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BACKGROUND: It is unclear what office blood pressure (BP) is the optimal treatment target range in patients with hypertension.
METHODS AND RESULTS: Using the Korean National Health Insurance Service database, we extracted the data on 479 359 
patients with hypertension with available BP measurements and no history of cardiovascular events from 2002 to 2011. The 
study end point was major cardiovascular events (MACE), a composite of cardiovascular death, myocardial infarction, or 
stroke. This cohort study evaluated the association of BP levels (<120/<70, 120– 129/70– 79, 130– 139/80– 89, 140– 149/90– 99, 
and ≥150/≥100 mm Hg) with MACE. During a median follow- up of 9 years, 55 401 MACE were documented in our cohort. The 
risk of MACE was the lowest (adjusted hazard ratio [HR], 0.79; 95% CI, 0.76– 0.84) at BP level of <120/<70 mm Hg, and was 
the highest (HR, 1.32; 95% CI, 1.29– 1.36) at ≥150/≥100 mm Hg in comparison with 130 to 139/80 to 89 mm Hg. These re-
sults were consistent in all age groups and both sexes. Among patients treated with antihypertensive medication (n=237 592, 
49.5%), in comparison with a BP level of 130 to 139/80 to 89 mm Hg, the risk of MACE was significantly higher in patients with 
elevated BP (≥140/≥90 mm Hg), but not significantly lower in patients with BP of <130/<80 mm Hg. Low BP <120/70 mm Hg 
was associated with increased risk of all- cause or cardiovascular death in all age groups.
CONCLUSIONS: BP level is significantly correlated with the risk of MACE in all Korean patients with hypertension. However, there 
were no additional benefits for MACE amongst those treated for hypertension with BP <120/70 mm Hg.
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Elevated blood pressure (BP) is a modifiable risk factor for cardiovascular morbidity and mor-tality.1 Previous guidelines recommended a target BP of <140/90 mm Hg to reduce cardiovascular events.2,3 However, SPRINT (Systolic Blood Pressure Intervention Trial) has reported in 2015 that a systolic 
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BP target of <120  mm  Hg instead of <140  mm  Hg 
lowers rates of major cardiovascular events (MACE) 
(fatal and non- fatal) and death from any cause among 
patients without diabetes mellitus at high risk for car-
diovascular events.4 The 2017 American College of 
Cardiology/American Heart Association and the 2018 
European Society of Cardiology/European Society of 
Hypertension guidelines recommended that the BP 
values should be 130/80  mm  Hg or lower in most 
treated patients.5,6 This recommendation was based 
on multiple meta- analyses that found that, in com-
parison with standard BP reduction, more intense BP 
lowering significantly reduces the risk of stroke, coro-
nary events, MACE, and cardiovascular mortality.4,7– 11 
On the other hand, other studies have reported that 
lowering systolic BP to <130 mm Hg in general has no 
further benefit in terms of major cardiovascular events 
except that it may reduce the risk of stroke.12– 14
There are some debates about optimal target BP in 
treatment of patients with hypertension, and there is a 
lack of evidence about target BP in Asian populations. 
Therefore, in this nationwide population– based study, 




This study used the National Health Information 
Database produced by the National Health Insurance 
Service (NHIS). The authors declare no conflict of 
interest with NHIS. The NHIS provides mandatory 
health insurance for all South Korean citizens, cover-
ing 97% of the Korean population.15 The NHIS claim 
database includes data on demographic charac-
teristics, diagnoses, prescriptions, health screen-
ing examination data (eg, health questionnaires and 
laboratory tests), and deaths. The details of the data-
base are described elsewhere.16 All diagnoses are re-
corded in the NHIS database using the International 
Classification of Diseases, Tenth Revision (ICD- 10) 
codes. The authors are restricted from sharing the 
data underlying this study because The Korean NHIS 
owns the data. This study was performed as a pro-
ject between the Korean Society of Hypertension and 
the NHIS. Researchers who are not members of the 
collaboration can request access on the NHIS web-
site (http://nhiss.nhis.or.kr). Details of this process 
and a provision guide are now available at https://
nhiss.nhis.or.kr/bd/ab/bdaba 032eng.do. This study 
was approved by the Institutional Review Board of 
Kangbuk Samsung Hospital (KBSMC 2020- 01- 043). 
The anonymized data set was provided to the re-
searchers by the NHIS and the requirement for in-
formed consent was waived.
Study Population
The cohort included 1  554  406 participants aged 
≥19  years who underwent health screening twice 
within 4  years by 2002 and 2011. Among them, we 
extracted 611  320 individuals who were diagnosed 
with hypertension (I10– I13, I15) before the first health 
screening examination. Finally, we enrolled 479 359 in-
dividuals after excluding those who had experienced 
myocardial infarction (I21– I23) or stroke (I60– I64) 
(n=62  039), were diagnosed with malignancy (C00– 
C99) (n=55 025) between the first and second health 
screenings, and whose data on baseline variables 
were missing (n=14  897). Individuals were followed 
up until death from any cause or the end of the study 
(December 2017), or censored when cardiovascular 
CLINICAL PERSPECTIVE
What Is New?
• Elevated office blood pressure (BP) 
(≥140/≥90 mm Hg) was significantly associated 
with increased major cardiovascular events 
in all patients with hypertension regardless of 
treatment with antihypertensive medication.
• In all patients with hypertension, office BP of 
<130/<80 mm Hg was significantly associated 
with lower major cardiovascular events com-
pared with ≥130/≥80  mm  Hg; this result was 
consistent regardless of sex or age except in 
men aged ≥70 years.
• There was no additional benefit of low 
BP <120/70  mm  Hg in comparison with 
<140/<90  mm  Hg for major cardiovascular 
events in patients treated with antihypertensive 
medication; this result was consistent in both 
men and women regardless of age.
What Are the Clinical Implications?
• Results of current analyses suggest “the lower, 
the better” for the overall BP control in all pa-
tients with hypertension.
• When we manage patients with hypertension 
with antihypertensive medication, BP target of 
<140/90 mm Hg appears to be reasonable for 
prevention of major cardiovascular events in 
clinical practice, and low BP <120/70 mm Hg 
might not be beneficial.
Nonstandard Abbreviations and Acronyms
MACE major cardiovascular events
NHIS National Health Insurance Service
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death, myocardial infarction, or stroke developed. 
Figure 1 shows a flowchart of the study population. We 
defined patients treated for hypertension as patients 
who were prescribed antihypertensive medications 
including angiotensin- converting enzyme inhibitors, 
angiotensin II receptor blockers, beta- adrenergic 
blockers, calcium channel blockers, or diuretics every 
year between the first and second health screenings.
Blood Pressure and End Point
BP was measured using either sphygmomanometers 
or oscillometric devices after 3 to 5  minutes of rest. 
The staff who performed the measurements was rec-
ommended to choose a cuff of appropriate size, and 
to repeat measurements ≥2 times at 1- to- 2- minute in-
tervals. Baseline BP was defined as the mean values 
of 2 BP measurements during different health screen-
ings, which we assumed to be representative of the 
overall BP levels. The study participants were catego-
rized arbitrary into 5 groups according to systolic and/
or diastolic BPs (<120 and <70 [extremely intensive BP 
reduction group], 120– 129 and/or 70– 79 [intensive BP 
reduction group], 130– 139 and/or 80– 89 [standard 
BP reduction group], 140– 149 and/or 90– 99 [lenient 
group], ≥150 and/or ≥100 mm Hg [uncontrolled group]) 
(Figure  S1). This categorization of the participants 
was based on the US guideline5 that a BP target of 
<130/80 mm Hg may be reasonable, and the European 
guideline6 that the first objective of treatment should be 
to lower BP to <140/ 90 mm Hg and reducing BP to 
<120/70 mm Hg should be cautious.
The primary end point was MACE, which was a 
composite of cardiovascular death, myocardial infarc-
tion, or stroke. Vital status and the cause of death were 
retrieved from the mortality records of the National 
Statistical Office of Korea. Cardiovascular death 
was defined according to the ICD- 10 codes I00– I99. 
Myocardial infarction was defined as a hospitalization 
with the ICD- 10 codes I21– 23 as primary or secondary 
diagnosis. Stroke (hemorrhagic or ischemic) was de-
fined by discharge diagnosis (ICD- 10 codes, I60– 64) 
among patients who had been hospitalized and under-
gone brain imaging studies such as computed tomog-
raphy or magnetic resonance imaging.17 We censored 
a primary end point using newly occurrence of the ICD- 
10 codes for cardiovascular death, myocardial infarc-
tion, or stroke. The censoring date was the earliest of 
the following: date of death, date of primary outcome, 
or end date of the study period (December 31, 2017).
Statistical Analysis
Data are reported as mean (SD) or median (interquar-
tile range) for continuous variables, and as numbers 
(percentages) for categorical variables. The incidence 
Figure 1. Flowchart of the study population. 
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rates were estimated using the total number of out-
comes during the follow- up divided by 100  000 
person- years. Cox proportional hazard models were 
used to evaluate the associations between base-
line BP levels and the risk of cardiovascular events. 
Hazard ratios were adjusted for age, sex, income 
level, history of smoking, physical activity, alcohol 
consumption, body mass index, fasting glucose, 
total cholesterol, diabetes mellitus, and medication 
of aspirin or statin, and are presented with 95% CIs. 
We further planned a subgroup analysis of sex, anti-
hypertensive drugs, and age groups that had differ-
ent clinical outcomes in previous studies, and tested 
heterogeneity using the interaction term. In the group 
whose interaction term was statistically significant, 
subgroup analysis was performed. We also analyzed 
the association between BP levels and the risk of 
major cardiovascular events including heart failure in 
patients without baseline heart failure (ICD- 10 codes, 
I11.0, I13.0, I13.2, I42, and I50). Statistical analyses 
were performed using SAS statistical software (ver-
sion 9.4, SAS Institute, Cary, NC) and R statistical 
software (version 3.6.1, R Foundation for Statistical 
Computing, Vienna, Austria).
RESULTS
Baseline Characteristics of the Study 
Population
A total of 479 359 subjects who were diagnosed with 
hypertension and who had available blood pressure 
measurements were identified. The mean age was 
58.6±11.7 years and 43.4% were men. The mean systolic 
and diastolic BPs were 132.7±12.8 and 81.4±8.0 mm Hg, 
respectively. Mean body mass index was 24.8±3.2 kg/
m2. The proportion of treated patients, ie, those who 
were prescribed anti- hypertensive medication, was 
49.5%. Table  1 shows baseline characteristics of the 
study population according to BP level. Tables S1 and 
S2 show baseline characteristics of the study popula-
tion separately for men and women, respectively.
Relationship Between Blood Pressure 
Levels and MACE
During 4 294 258 person- years of follow- up (median fol-
low- up, 9 years; interquartile range, 7– 11 years), we ob-
served 55 401 MACE (incidence rate, 1290 per 100 000 
person- years): 12  087 cardiovascular deaths, 9324 
myocardial infarctions, and 40 774 strokes. MACE oc-
curred in 26 696 men (incidence rate, 1400 per 100 000 
person- years) and 28 705 women (incidence rate, 1201 
per 100 000 person- years). Table 2 details the incidences 
and adjusted hazard ratio (HR) of MACE according to 
BP levels. After adjusting all variables, the risk of MACE 
was the lowest in patients with <120/70 mm Hg and the 
highest in those with ≥150/≥100 mm Hg. This trend was 
consistent between men and women (Table S3). Among 
the components of MACE, the risk of stroke was sig-
nificantly correlated with BP level, but the risks of car-
diovascular death and myocardial infarction were not 
significantly lower in patients with <130/<80 mm Hg than 
in the reference group (130– 139/80– 89 mm Hg) in both 
men and women (Table 2 and Table S3). Figure 2 shows 
BP levels and adjusted HR for MACE in all patients with 
hypertension according to age category. Linear corre-
lations between BP levels and adjusted HR of MACE 
were observed in all patient groups except men aged 
≥70 years. The risk of MACE according to BP increments 
in all patients with hypertension is shown in Table 3. The 
incidences and adjusted HR of MACE including heart 
failure according to BP levels in patients without baseline 
heart failure (n=461  492) are shown in Tables  S4 and 
S5. Even in the composite events including heart failure, 
the results were not different. Details of the correlations 
between BP levels and all- cause mortality and MACE 
by sex for different age groups are shown in Tables S6 
through S9. Cardiovascular death is significantly in-
creased in the lowest BP level compared with reference 
BP level in both men and women with ≥70 years, but risk 
for MACE is not increased significantly.
Relationship Between Blood Pressure 
Levels and MACE in Patients Treated for 
Hypertension
Table  4 shows the incidence of MACE according to 
BP levels among patients treated for hypertension. 
In multivariable analysis, the incidence of MACE in-
creased significantly higher at ≥140/≥90 mm Hg than 
at the reference BP level (130– 139/80– 89  mm  Hg), 
but it was not significantly lower at lower BP levels 
(<130/<80  mm  Hg). This result was consistent be-
tween men and women (Table S10). Among the com-
ponents of MACE, the risk of stroke was significantly 
decreased at BP levels lower than the reference BP 
level. However, low BP <130/80  mm  Hg was not 
beneficial for the prevention of cardiovascular death 
or myocardial infarction. Figure 3 shows the relation-
ship between BP levels and adjusted HR for MACE 
in treated hypertensive patients of different age cat-
egories. Significant risk reduction of MACE at low 
BP levels (<130/<80  mm  Hg) was observed only in 
some of the age categories. Rather, patients with BP 
<120/<70 mm Hg had higher risk of all- cause or car-
diovascular death than those with the reference BP 
level in all age categories (Tables S6 through S9). This 
trend was also consistent when analyzing the patient 
group excluding heart failure (Table S5). The restricted 
cubic spline curves for the risk of MACE according to 
systolic and diastolic BP levels are shown in Figure 4.
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Sensitivity Analyses in Patients Without 
Taking Antihypertensive Medications and 
in Those Without Diabetes Mellitus
We further analyzed whether the relationship be-
tween blood pressure levels and major cardio-
vascular events had consistent results in patients 
who did not take antihypertensive medications 
(Table  S11) or who did not have diabetes mellitus 
(Table S12). Even in patients without diabetes melli-
tus, the higher the blood pressure than the reference 
BP (130– 139/80– 89  mm  Hg), the higher the risk of 
MACE. However, patients with BP <120/70 mm Hg 
had higher risk of all- cause or cardiovascular death 
than those with the reference BP.
Table 1. Baseline Characteristics of the Study Population According to Blood Pressure Level
Blood Pressure Level (mm Hg)
P Value<120/<70 120– 129/70– 79 130– 139/80– 89 140– 149/90– 99 ≥150/≥100
No. of patients (%) 23 756 (4.9) 117 941 (24.6) 193 552 (40.3) 98 593 (20.5) 45 517 (9.5) <0.001
Age, y 54 (45– 60) 58 (50– 66) 59 (51– 67) 60 (52– 68) 64 (54– 70) <0.001
Sex (%) <0.001
Men 6232 (26.2) 45 274 (38.4) 88 658 (45.8) 46 719 (47.4) 21 492 (47.2)
Women 17 524 (73.8) 72 667 (61.6) 104 894 (54.2) 51 874 (52.6) 24 025 (52.8)
Blood pressure, mm Hg
Systolic blood pressure 109.1±6.4 121.2±5.6 131.9±5.0 142.7±4.2 156.8±7.9 <0.001
Diastolic blood pressure 65.5±3.3 74.7±3.3 81.9±4.1 82.3±5.6 92.6±7.9 <0.001
Household income (%) <0.001
First (highest) 8377 (35.3) 40 920 (34.7) 66 682 (34.4) 33 060 (33.5) 14 308 (31.4)
Second 5821 (24.5) 29 078 (24.7) 48 248 (24.9) 24 831 (25.2) 11 275 (24.8)
Third 4593 (19.3) 22 631 (19.2) 36 783 (19.0) 19 061 (19.3) 9325 (20.5)
Fourth (lowest) 4965 (20.9) 25 312 (21.4) 41 839 (21.6) 21 641 (22.0) 10 609 (23.3)
Smoking (%) <0.001
Never 18 570 (78.2) 85 362 (72.4) 134 668 (69.6) 68 669 (69.6) 32 350 (71.1)
Past 2147 (9.0) 15 422 (13.1) 30 339 (15.7) 15 548 (15.8) 6279 (13.8)
Current 3039 (12.8) 17 157 (14.5) 28 545 (14.7) 14 376 (14.6) 6888 (15.1)
Physical activity, times/wk (%) <0.001
0 12 859 (54.1) 63 908 (54.2) 102 337 (52.9) 53 963 (54.7) 26 583 (58.4)
1– 2 3841 (16.2) 17 254 (14.6) 28 409 (14.7) 14 091 (14.3) 6397 (14.1)
3– 4 2852 (12.0) 13 969 (11.8) 23 380 (12.1) 11 278 (11.4) 4557 (10.0)
5– 6 1884 (7.9) 9860 (8.4) 16 829 (8.7) 7989 (8.1) 3051 (6.7)
7 2320 (9.8) 12 950 (11.0) 22 597 (11.6) 11 272 (11.4) 4929 (10.8)
Alcohol consumption, times/wk (%) <0.001
0 17 807 (74.9) 82 441 (69.9) 125 907 (65.0) 62 663 (63.6) 28 918 (63.5)
<1 3014 (12.7) 14 773 (12.5) 24 467 (12.6) 11 465 (11.6) 4732 (10.4)
1– 2 2039 (8.6) 14 113 (12.0) 28 861 (14.9) 15 530 (15.7) 7060 (15.5)
3– 4 486 (2.0) 3583 (3.0) 7881 (4.1) 4693 (4.8) 2442 (5.3)
≥5 410 (1.7) 3031 (2.6) 6436 (3.3) 4242 (4.3) 2365 (5.2)
Body mass index, kg/m2 23.1±3.0 24.4±3.1 25.0±3.2 25.3±3.3 25.3±3.5 <0.001
Glucose, mg/dL 98.3±27.1 103.0±29.1 105.4±29.3 107.7±31.3 110.5±35.4 <0.001
Total cholesterol, mg/dL 191.2±40.7 194.9±39.9 197.0±40.7 198.9±42.3 201.6±45.2 <0.001
Diabetes mellitus (%) 2892 (12.1) 14 823 (12.5) 20 804 (10.7) 10 097 (10.2) 4802 (10.5) <0.001
Aspirin (%) 4213 (17.7) 27 713 (23.5) 50 588 (26.1) 26 127 (26.5) 11 802 (25.9) <0.001
Statin (%) 3275 (13.7) 17 234 (14.6) 25 649 (33.4) 32 535 (33.0) 14 520 (31.9) <0.001
Anti- hypertensive medication (%) 6555 (27.5) 51 304 (43.5) 100 112 (51.7) 54 073 (54.8) 25 548 (56.1) <0.001
Data are expressed as mean±SD, median (interquartile range), or number (percentage).
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DISCUSSION
In this nationwide cohort study, we have revealed that 
(1) elevated BP is a strong predictor of future MACE 
including cardiovascular death, myocardial infarc-
tion, or stroke; (2) BP level is significantly correlated 
with the risk of MACE, especially the incidence of 
stroke, in all patients with hypertension; however, (3) 
there is no further benefit of low BP <130/80 mm Hg 
in comparison with <140/90 mm Hg for MACE in pa-
tients treated with antihypertensive medication; and 
(4) low BP <120/70  mm  Hg was associated with a 
higher risk of all- cause or cardiovascular death in all 
age groups.
Although current guidelines recommend a target 
BP level of <130/80  mm  Hg, there is no consensus 
on the optimal BP target in the treatment of hyperten-
sion. SPRINT trial, which was relevant to this issue, 
showed that intensive treatment (systolic BP target of 
<120  mm  Hg) was associated with a 25% reduction 
in MACE and a 27% reduction in all- cause mortality 
in comparison with conventional treatment (systolic 
BP target of <140 mm Hg).4 However, this trial relied 
on unattended automatic office BP measurements, 
which had not been used in any previous random-
ized trials.18 Such measurements are known to result 
in lower BP values than conventional office BP mea-
surements, because of the absence of the white- coat 
effect.19,20 Thus, it has been suggested that the BP val-
ues (121.5 mm Hg in intensive- treatment group versus 
134.6 mm Hg in standard- treatment group) reported in 
SPRINT may correspond to conventional office systolic 
BP in the 130 to 140 and 140 to 150 mm Hg ranges in 
the intensive versus conventional BP- lowering groups, 
respectively.6
In this nationwide cohort, all BP measurement 
methods could not be determined. However, most of 
the BP measurements must have been performed by 
an attending nurse or physician. Despite this, the ben-
efit of low BP <130/80 mm Hg for MACE was found 
in all patients with hypertension except men aged 
≥70 years, but not in patients treated for hypertension. 
These discordant results can be explained in several 
ways. First, in our study, patients with hypertension 
without antihypertensive medication were younger 
and had lower BP values, lower body mass index, 
Table 2. Incidences of Major Cardiovascular Events According to Blood Pressure Level in All Patients With Hypertension
Blood Pressure, mm Hg Events (n) Person- Years
Incidence (Events/100 000 
Person- Years) Adjusted HR (95% CI)
Cardiovascular death
<120/<70 440 203 249 216 1.18 (1.07– 1.30)
120– 129/70– 79 2370 1 067 813 222 1.00 (0.95– 1.05)
130– 139/80– 89 4220 1 820 120 232 1.00 (reference)
140– 149/90– 99 2907 921 915 315 1.19 (1.14– 1.25)
≥150/≥100 2150 402 612 534 1.61 (1.52– 1.69)
MI
<120/<70 329 209 593 157 0.90 (0.81– 1.01)
120– 129/70– 79 2124 1 095 879 194 1.00 (0.95– 1.06)
130– 139/80– 89 3688 1 871 002 197 1.00 (reference)
140– 149/90– 99 2058 959 597 214 1.04 (0.99– 1.1.0)
≥150/≥100 1125 432 195 260 1.18 (1.10– 1.26)
Stroke
<120/<70 1095 205 177 534 0.69 (0.65– 0.73)
120– 129/70– 79 8156 1 059 686 770 0.88 (0.86– 0.91)
130– 139/80– 89 15 929 1 794 934 887 1.00 (reference)
140– 149/90– 99 9855 909 679 1083 1.14 (1.11– 1.17)
≥150/≥100 5739 402 547 1426 1.31 (1.27– 1.35)
Cardiovascular death or MI or stroke
<120/<70 1676 202 047 830 0.79 (0.76– 0.84)
120– 129/70– 79 11 362 1 042 767 1090 0.92 (0.90– 0.94)
130– 139/80– 89 21 460 1 765 485 1216 1.00 (reference)
140– 149/90– 99 13 112 892 521 1469 1.12 (1.10– 1.15)
≥150/≥100 7791 391 437 1990 1.32 (1.29– 1.36)
HR was adjusted for age, sex, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, and 
medication (aspirin or statin), and antihypertensive medication. HR indicates hazard ratio; and MI, myocardial infarction.
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Figure 2. Baseline blood pressure levels and adjusted hazard ratios for major cardiovascular 
events in all patients with hypertension according to age category.
A, Aged <50 years, (B) aged 50 to 59 years, (C) aged 60 to 69 years, (D) aged ≥70 years. Major cardiovascular 
events were defined as a composite of cardiovascular death, myocardial infarction, and stroke. BP indicates 
blood pressure; and HR, hazard ratio.
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Figure 2. Continued
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lower fasting glucose, and lower prevalence of diabe-
tes mellitus than treated patients. Second, because 
patients not medicated for hypertension constitute 
a large proportion of low- BP groups, these popula-
tions may implement lifestyle intervention well. On 
the other hand, because patients medically treated 
for hypertension are much more represented in high-
er- BP groups, these patients may have advanced 
vascular pathologies such as arterial stiffness and 
large pulse pressure values. Third, a few patients not 
medicated for hypertension might be misdiagnosed 
with hypertension because of the white- coat effect. 
Therefore, after patients not medicated for hyperten-
sion were excluded, the number of treated patients in 
low- BP groups was lower than in other groups; thus, 
the benefit of lowering BP for future cardiovascular 
events might have disappeared. In addition, our re-
sults support “the lower, the better” in BP control at 
Table 3. Risk of Major Cardiovascular Events According to Blood Pressure Increments in All Patients With Hypertension
Systolic Blood Pressure (mm Hg) Diastolic Blood Pressure (mm Hg)
Per 20 mm Hg Per 10 mm Hg 1- SD Per 20 mm Hg Per 10 mm Hg 1- SD
In total population
Adjusted HR (95% CI) 1.23 (1.21– 1.25) 1.11 (1.10– 1.12) 1.14 (1.13– 1.15) 1.38 (1.35– 1.41) 1.18 (1.16– 1.19) 1.14 (1.13– 1.15)
In men
Adjusted HR (95% CI) 1.22 (1.20– 1.25) 1.11 (1.10– 1.12) 1.14 (1.12– 1.15) 1.30 (1.26– 1.34) 1.14 (1.12– 1.16) 1.11 (1.10– 1.13)
In women
Adjusted HR (95% CI) 1.21 (1.19– 1.23) 1.10 (1.09– 1.11) 1.13 (1.12– 1.15) 1.39 (1.34– 1.43) 1.18 (1.16– 1.20) 1.14 (1.13– 1.15)
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, diabetes mellitus, 
medication of aspirin or statin, and antihypertensive medication. HR indicates hazard ratio.
Table 4. Incidences of Major Cardiovascular Events According to Blood Pressure Level in Patients Treated for 
Hypertension
Blood Pressure (mm Hg) Events (n) Person- Years
Incidence (Events/100 000 
Person- Years) Adjusted HR (95% CI)
Cardiovascular death
<120/<70 251 23 191 1082 1.70 (1.49– 1.94)
120– 129/70– 79 1225 450 400 272 1.09 (1.02– 1.17)
130– 139/80– 89 2183 910 024 240 1.00 (reference)
140– 149/90– 99 1545 486 613 318 1.19 (1.11– 1.27)
≥150/≥100 1139 219 428 519 1.57 (1.46– 1.69)
MI
<120/<70 134 55 833 240 1.08 (0.90– 1.28)
120– 129/70– 79 1034 463 106 223 1.08 (1.00– 1.16)
130– 139/80– 89 1872 935 410 200 1.00 (reference)
140– 149/90– 99 1043 506 155 206 1.00 (0.93– 1.08)
≥150/≥100 623 234 314 266 1.20 (1.09– 1.31)
Stroke
<120/<70 438 54 152 809 0.80 (0.73– 0.89)
120– 129/70– 79 3784 447 167 846 0.90 (0.87– 0.94)
130– 139/80– 89 8091 898 319 901 1.00 (reference)
140– 149/90– 99 5127 481 293 1065 1.12 (1.08– 1.15)
≥150/≥100 3028 219 361 1380 1.28 (1.22– 1.33)
Cardiovascular death or MI or stroke
<120/<70 728 52 660 1382 0.99 (0.92– 1.07)
120– 129/70– 79 5418 438 920 1234 0.96 (0.93– 0.99)
130– 139/80– 89 10 943 883 940 1238 1.00 (reference)
140– 149/90– 99 6843 472 686 1448 1.10 (1.07– 1.13)
≥150/≥100 4151 213 621 1943 1.30 (1.25– 1.35)
Hazard ratio was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, and 
medication (aspirin or statin). HR indicates hazard ratio; and MI, myocardial infarction.
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Figure 3. Baseline blood pressure levels and adjusted hazard ratios for major cardiovascular 
events in patients treated for hypertension according to age category.
A, Aged <50 years, (B) aged 50 to 59 years, (C) aged 60 to 69 years, (D) aged ≥70 years. Major cardiovascular 
events were defined as a composite of cardiovascular death, myocardial infarction, and stroke. BP indicates 
blood pressure; and HR, hazard ratio.
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Figure 3. Continued
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an early hypertension stage and/or in young patients 
with hypertension. This result is consistent with previ-
ous Korean analyses, which showed that normal BP 
range (<120/<80 mm Hg) is associated with the low-
est cardiovascular risk in comparison with the upper 
BP ranges in the general population21,22 and in young 
patients with hypertension.23,24 In young patients with 
hypertension and at an early stage of the disease, low-
ering BP below the normal BP level should be benefi-
cial regardless of medication or lifestyle modification.
In our study, no benefit of low BP <130/80 mm Hg for 
prevention of MACE was observed in treated patients 
with hypertension. Moreover, low BP <120/70 mm Hg 
was associated with increased risk of all- cause or car-
diovascular death in all age categories. The lower safety 
boundary of BP control has not been decided yet in 
high- cardiovascular- risk or elderly patients. Previous 
studies on high- risk patients reported that lowering 
systolic BP to <130 mm Hg significantly reduces the 
risk of cardiovascular disease,9,10 but reduction of sys-
tolic BP to <120 mm Hg or diastolic BP to <70 mm Hg 
is associated with an increase in the incidence of car-
diovascular events.12 A Korean study using NHIS data 
showed a J- curve pattern between BP levels and 
ischemic heart disease or acute myocardial infarction 
in patients aged 70 to 80 years without known hyper-
tension.25 Furthermore, lower baseline diastolic BP is 
reportedly associated with increased risk of cardiovas-
cular events.26,27 Currently, American and European 
guidelines recommend that the target BP should be 
130/80 mm Hg, but the target systolic BP should not 
be <120 mm Hg in elderly patients (>65 years).5,6 Our 
results support these recommendations. Thus, it is 
recommended to should be careful when performing 
intensive BP control in elderly patients.
This study has several limitations. First, it was a ret-
rospective cohort study, and thus had the inherent lim-
itations of this type of analysis. However, the use of the 
national registration data ensured that the treatment 
status of the study population was known, no cardio-
vascular outcomes were missed, and the chance of 
attrition bias was low. Seconds, since this is an obser-
vational study, it is inevitable to be criticized for whether 
the low BP at a single point reflects the strict controlled 
BP. It was also impossible to exclude all other sys-
temic conditions at single point. Especially, we could 
not exclude the reverse causality between all- cause 
mortality, to some extent cardiovascular death, and 
low BP levels. Therefore, it cannot be concluded by 
generalizing the target BP in patients treated for hyper-
tension based on the results of our study. Third, it was 
not possible to determine exactly what are the events 
that drive the increase in CV death in our study. Indeed, 
there was no signal of increase in MI or stroke, indeed 
for the latter it was beneficial. However, our study is 
sufficient to support that low BP below 120/70 mm Hg 
might not at least be beneficial in patients treated 
with antihypertensive medication. Fourth, this study 
Figure 4. The relationship between baseline systolic and diastolic blood pressures and major 
cardiovascular events in patients treated for hypertension. 
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population was of homogeneous Korean ethnicity, 
and hypertensive patients with the past MACE were 
excluded, so caution is required to generalize the find-
ings of this study to other ethnic groups or high- risk 
populations. Fifth, we used only baseline BP, but did 
not incorporate the follow- up BP data in our analysis. 
Thus, we evaluated the longitudinal effect of baseline 
BP levels, but could not evaluate the effect of follow- up 
BP. Sixth, prescription of anti- hypertensive medication 
was evaluated at baseline time. However, we did not 
evaluate continuous prescription of medication during 
follow- up. Thus, we could not incorporate the effect of 
medication compliance in our analysis. In addition, we 
could not evaluate treatment pattern or dose of med-
ication, which might influence BP levels. Seventh, we 
extracted patients with hypertension between 2002 
and 2012. At this period, hypertension was defined as 
≥140 and/or ≥90 mm Hg according to The Sixth and 
Seventh Reports of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of 
High Blood Pressure.28,29 So, there is inconsistency of 
hypertension definition between this study and current 
American guidelines. Finally, even subgroup analysis 
of patients without heart failure had consistent results, 
but we could not exclude all the patients with any 
cardiovascular disease like angina, peripheral arterial 
disease or patients with history of revascularization. 
Therefore, it cannot be concluded by generalizing the 
target BP in patients treated for hypertension based on 
the results of our study. However, our study was worth-
while because that it was a nationwide study with a 
large sample size and long- term follow- up periods and 
we had consistent results that low BP <120/70 mm Hg 
might not at least be beneficial, even when we reana-
lyzed the subgroup without heart failure. Based on our 
findings, well- designed studies related to the BP goal 
in patients treated for hypertension are needed.
CONCLUSIONS
Elevated BP is a strong predictor for future MACE in 
all Korean patients with hypertension. However, in pa-
tients treated with antihypertensive medication, low BP 
<120/70 mm Hg might not at least be beneficial for the 
prevention of MACE.
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SUPPLEMENTAL MATERIAL
Table S1. Baseline Characteristics of the Study Population According to Blood Pressure Level among Men. 
Blood Pressure Level (mmHg) 
<120/<70 120–129/70–79 130–139/80–89 140–149/90–99 ≥150/≥100 
Number of patients (%) 
6,232 (2.99) 45,274 (22.40) 88,658 (43.86) 46,719 (23.11%) 21,492 (10.63) 
Age (years) 
58 (48–68) 57 (48–66) 57 (48–65) 58 (4–66) 60 (50–68) 
Blood pressure (mmHg) 
  Systolic blood pressure 110.52 ± 5.93 121.44 ± 5.41 131.74 ± 5.06 142.45 ± 4.40 156.88 ± 8.23 
  Diastolic blood pressure 65.85 ± 3.12 75.01 ± 3.24 82.38 ± 3.98 88.08 ± 5.51 93.95 ± 8.16 
Household income (%) 
First (highest) 
2,314 (37.13) 16,119 (35.60) 31,216 (35.21) 15,573 (33.33) 6,348 (29.54) 
  Second 
1,624 (26.06) 11,759 (25.97) 23,037 (25.98) 12,107 (25.91) 5,478 (25.49) 
  Third 
1,191 (19.11) 9,080 (20.06) 17,338 (19.56) 9,316 (19.94) 4,699 (21.86) 
  Fourth (lowest) 
1,103 (17.70) 8,316 (18.37) 17,067 (19.25) 9,723 (20.81) 4,967 (23.11) 
Smoking (%) 
  Never 2,162 (34.69) 15,864 (35.04) 33,189 (37.43) 18,227 (39.01) 8,992 (41.84) 
  Past 1,813 (29.09) 14,472 (31.97) 29,286 (33.03) 15,086 (32.29) 6,080 (28.29) 
  Current 2,257 (36.22) 14,938 (32.99) 26,183 (29.53) 13,406 (28.69) 6,420 (29.87) 
Physical activity, times/week (%)      
  0 3,070 (49.26) 20,712 (45.75) 38,818 (43.78) 21,200 (45.38) 10,717 (49.87) 
  1–2 1,078 (17.30) 8,007 (17.69) 15,619 (17.62) 8,053 (17.24) 3,675 (17.10) 
  3–4 806 (12.93) 6,186 (13.66) 12,514 (14.11) 6,419 (13.74) 2,550 (11.86) 
  5–6 520 (8.34) 4,406 (9.73) 9,077 (10.24) 4,501 (9.63) 1,721 (8.01) 
  7 758 (12.16) 5,963 (13.17) 12,630 (14.25) 6,546 (14.01) 2,829 (13.16) 
Alcohol consumption, times/week 
(%) 
     
  0 3,301 (52.97) 20,111 (44.42) 34,759 (39.21) 17,096 (36.59) 7,713 (35.89) 
  <1 1,133 (18.18) 8,575 (18.94) 16,503 (18.61) 7,934 (16.98) 3,233 (15.04) 
  1–2 1,171 (18.79) 10,939 (24.16) 24,524 (27.66) 13,454 (28.80) 6,095 (28.36) 
  3–4 347 (5.57) 3,092 (6.83) 7,199 (8.12) 4,373 (9.36) 2,271 (10.57) 
  ≥5 280 (4.49) 2,557 (5.65) 5,673 (6.40) 3,862 (8.27) 2,180 (10.14) 
Body mass index (kg/m2)  23.18 ± 2.87 24.40 ± 2.99 25.01 ± 3.03 25.22 ± 3.19 25.11 ± 3.38 
Glucose (mg/dl)  103.81 ± 35.60 105.95 ± 32.29 107.81 ± 31.56 110.17 ± 33.49 113.24 ± 38.54 
Total cholesterol (mg/dl)  182.96 ± 47.69 187.47 ± 37.80 190.77 ± 39.66 192.85 ± 40.19 195.02 ± 40.69 
Diabetes mellitus (%) 1,011 (16.22) 6,197 (13.69) 9,852 (11.11) 4,868 (10.42) 2,194 (10.21) 
Aspirin (%) 1,675 (26.88) 11,912 (26.31) 24,070 (27.15) 12,346 (26.43) 5,385 (25.06) 
Statin (%) 908 (14.57) 6,192 (13.68) 10,720 (12.09) 4,917 (10.52) 1,990 (9.26) 
Anti-hypertensive medication (%) 2,169 (34.80) 19,939 (44.04) 44,284 (49.95) 24,186 (51.77) 11,153 (51.89) 
Data are expressed as mean ± standard deviation, median (interquartile range), or number (percentage). 
 
Table S2. Baseline Characteristics of the Study Population According to Blood Pressure Level among Women. 
 Blood Pressure Level (mmHg) 
 <120/<70 120–129/70–79 130–139/80–89 140–149/90–99 ≥150/≥100 
Number of patients (%) 17,524 (6.47) 72,667 (28.67) 104,894 (41.38) 51,874 (20.47) 24,025 (9.48) 
Age (years) 53 (44–62) 58 (51–66) 60 (53–68) 62 (55–70) 66 (57–72) 
Blood pressure (mmHg)      
  Systolic blood pressure 108.64 ± 6.48 121.07 ± 5.76 132.01 ± 5.00 142.93 ± 4.01 156.78 ± 7.65 
  Diastolic blood pressure 65.36 ± 3.28 74.52 ± 3.31 25.09 ± 3.35 86.54 ± 5.57 91.45 ± 7.52 
Household income (%)      
 First (highest) 6,063 (34.60) 24,801 (34.13) 35,466 (33.81) 17,487 (33.71) 7,960 (33.13) 
  Second 4,197 (23.95) 17,319 (23.83) 25,211 (24.03) 12,724 (24.53) 5,797 (24.13) 
  Third 3,402 (19.41) 13,551 (18.65) 19,445 (18.54) 9,745 (18.79) 4,626 (19.25) 
  Fourth (lowest) 3,862 (22.04) 16,996 (23.39) 24,772 (23.62) 11,918 (22.97) 5,642 (23.48) 
Smoking (%)      
  Never 16,408 (93.63) 69,498 (95.64) 101,479 (96.74) 50,442 (97.24) 23,358 (97.22) 
  Past 334 (1.91) 950 (1.31) 1,053 (1.00) 462 (0.89) 199 (0.83) 
  Current 782 (4.46) 2,219 (3.05) 2,362 (2.25) 970 (1.87) 468 (1.95) 
Physical activity, times/week (%)      
  0 9,789 (55.86) 43,196 (59.44) 63,519 (60.56) 32,763 (63.16) 15,866 (66.04) 
  1–2 2,763 (15.77) 9,247 (12.73) 12,790 (12.19) 6,038 (11.64) 2,722 (11.33) 
  3–4 2,046 (11.68) 7,783 (10.71) 10,866 (10.36) 4,859 (9.37) 2,007 (8.35) 
  5–6 1,364 (7.78) 5,454 (7.51) 7,752 (7.39) 3,488 (6.72) 1,330 (5.54) 
  7 1,562 (8.91) 6,987 (9.62) 9,967 (9.50) 4,726 (9.11) 2,100 (8.74) 
Alcohol consumption, times/week 
(%) 
     
  0 14,506 (82.78) 62,330 (85.77) 91,148 (86.90) 45,567 (87.84) 21,205 (88.26) 
  <1 1,881 (10.73) 6,198 (8.53) 7,964 (7.59) 3,531 (6.81) 1,499 (6.24) 
  1–2 868 (4.95) 3,174 (4.37) 4,337 (4.13) 2,076 (4.00) 965 (4.02) 
  3–4 139 (0.79) 491 (0.68) 682 (0.65) 320 (0.62) 171 (0.71) 
  ≥5 130 (0.74) 474 (0.65) 763 (0.73) 380 (0.73) 185 (0.77) 
Body mass index (kg/m2)  23.09 ± 3.08 24.43 ± 3.25 25.09 ± 3.35 25.38 ± 3.47 25.47 ± 3.70 
Glucose (mg/dl)  96.39 ± 23.08 101.23 ± 26.80 103.38 ± 27.25 105.53 ± 29.01 108.04 ± 32.24 
Total cholesterol (mg/dl)  194.21 ± 37.50 199.55 ± 40.46 202.35 ± 40.96 204.46 ± 43.41 207.61 ± 48.24 
Diabetes mellitus (%) 1,881 (10.73) 8,626 (11.87) 10,952 (11.54) 5,229 (10.08) 2,608 (10.86) 
Aspirin (%) 2,538 (14.48) 15,801 (21.74) 26,518 (25.28) 13,781 (26.57) 6,417 (26.71) 
Statin (%) 2,367 (13.51) 11,042 (15.20) 14,929 (14.23) 6,999 (13.49) 3,095 (12.88) 
Anti-hypertensive medication (%) 4,386 (25.03) 31,365 (43.16) 55,828 (53.22) 29,887 (57.61) 14,395 (59.92) 
Data are expressed as mean ± standard deviation, median (interquartile range), or number (percentage). 
 
Table S3. Incidences of Major Cardiovascular Events According to Blood Pressure Level and Sex in All Hypertensive Patients. 
Blood pressure (mmHg) Events (n) Person-years Incidence  
(events/100,000 person-years) 
Adjusted HR (95% CI) 
In men     
Cardiovascular death     
  <120/<70 220 52,019 423 1.32 (1.14–1.51) 
  120–129/70–79 1,131 412,540 274 1.03 (0.95–1.10) 
  130–139/80–89 2,126 849,679 250 1.00 (reference) 
  140–149/90–99 1,476 443,447 333 1.21 (1.14–1.30) 
  ≥150/≥100 1,047 189,449 553 1.65 (1.53–1.78) 
MI     
  <120/<70 169 55,612 304 1.06 (0.90–1.24) 
  120–129/70–79 1,182 428,001 276 1.06 (0.99–1.14) 
  130–139/80–89 2,183 879,137 248 1.00 (reference) 
  140–149/90–99 1,170 465,919 251 1.01 (0.94–1.08) 
  ≥150/≥100 588 207,148 284 1.08 (0.99–1.19) 
Stroke     
  <120/<70 418 54,055 773 0.74 (0.67–0.82) 
  120–129/70–79 3,465 414,244 836 0.91 (0.88–0.95) 
  130–139/80–89 7,375 846,043 872 1.00 (reference) 
  140–149/90–99 4,645 442,992 1,049 1.14 (1.10–1.18) 
  ≥150/≥100 2,758 193,099 1,428 1.37 (1.31–1.43) 
Cardiovascular death or MI or stroke 
  <120/<70 714 52,464 1,361 0.90 (0.83–0.97) 
  120–129/70–79 5,192 404,558 1,283 0.96 (0.93–0.99) 
  130–139/80–89 10,541 828,466 1,272 1.00 (reference) 
  140–149/90–99 6,439 433,203 1,486 1.11 (1.08–1.15) 
  ≥150/≥100 3,810 187,252 2,035 1.35 (1.30–1.40) 
In women     
Cardiovascular death     
  <120/<70 220 151,230 145 1.15 (1.00–1.33) 
  120–129/70–79 1,239 655,273 189 1.02 (0.95–1.09) 
  130–139/80–89 2,094 970,441 216 1.00 (reference) 
  140–149/90–99 1,431 478,468 299 1.17 (1.09–1.25) 
  ≥150/≥100 1,103 213,163 517 1.55 (1.44–1.67) 
MI     
  <120/<70 160 153,981 104 0.93 (0.79–1.09) 
  120–129/70–79 942 667,878 141 1.00 (0.93–1.09) 
  130–139/80–89 1,505 991,865 152 1.00 (reference) 
  140–149/90–99 888 493,678 180 1.08 (1.00–1.18) 
  ≥150/≥100 537 225,048 239 1.26 (1.14–1.40) 
Stroke     
  <120/<70 677 151,122 448 0.67 (0.62–0.73) 
  120–129/70–79 4,691 645,443 727 0.87 (0.84–0.90) 
  130–139/80–89 8,554 948,891 901 1.00 (reference) 
  140–149/90–99 5,210 466,687 1,116 1.13 (1.09–1.17) 
  ≥150/≥100 2,981 209,448 1,423 1.25 (1.20–1.31) 
Cardiovascular death or MI or stroke 
  <120/<70 962 149,583 643 0.78 (0.73–0.83) 
  120–129/70–79 6,170 638,209 967 0.91 (0.88–0.94) 
  130–139/80–89 10,919 937,020 1,165 1.00 (reference) 
  140–149/90–99 6,673 459,318 1,453 1.12 (1.09–1.16) 
  ≥150/≥100 3,981 204,186 1,950 1.29 (1.24–1.34) 
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
diabetes mellitus, medication (aspirin or statin), and antihypertensive medication. CI, confidence interval; HR, hazard ratio; and MI, myocardial 
infarction. 
 
Table S4. Incidences of Major Cardiovascular Events including Heart Failure According to Blood Pressure Level in All Hypertensive 
Patients without baseline heart failure. 
Blood pressure (mmHg) Events (n) Person-years Incidence  
(events/100,000 person-years) 
Adjusted HR (95% CI) 
In total population     
Cardiovascular death  
  <120/<70 303 192,246 158 1.02 (0.90–1.14) 
  120–129/70–79 1,964 1,023,864 192 0.98 (0.93–1.03) 
  130–139/80–89 3,730 1,763,644 211 1.00 (reference) 
  140–149/90–99 2,616 894,075 293 1.21 (1.15–1.27) 
  ≥150/≥100 1,944 389,510 499 1.63 (1.54–1.72) 
MI 
  <120/<70 269 197,313 136 0.92 (0.82–1.05) 
  120–129/70–79 1,868 1,048,385 178 1.03 (0.97–1.09) 
  130–139/80–89 3,292 1,810,760 182 1.00 (reference) 
  140–149/90–99 1,835 929,072 198 1.04 (0.98–1.10) 
  ≥150/≥100 985 417,192 236 1.16 (1.08–1.24) 
Stroke 
  <120/<70 911 193,623 471 0.67 (0.62–0.71) 
  120–129/70–79 7,192 1,016,272 708 0.88 (0.85–0.90) 
  130–139/80–89 14,484 1,740,804 832 1.00 (reference) 
  140–149/90–99 8,943 883,074 1,013 1.13 (1.10–1.16) 
  ≥150/≥100 5,185 389,953 1,330 1.30 (1.26–1.34) 
Heart failure 
  <120/<70 578 195,815 295 1.30 (1.19–1.42) 
  120–129/70–79 3,190 1,042,018 306 1.13 (1.08–1.18) 
  130–139/80–89 5,089 1,802,330 282 1.00 (reference) 
  140–149/90–99 2,901 923,436 314 1.03 (0.98–1.07) 
  ≥150/≥100 1,633 413,916 395 1.13 (1.07–1.20) 
Cardiovascular death or MI or stroke or heart failure 
  <120/<70 1939 188,038 1,031 0.86 (0.82–0.90) 
  120–129/70–79 13,200 983,397 1,342 0.96 (0.94–0.98) 
  130–139/80–89 24,626 1,685,373 1,461 1.00 (reference) 
  140–149/90–99 14,869 850,720 1,748 1.11 (1.08–1.13) 
  ≥150/≥100 8,723 370,389 2,355 1.30 (1.27–1.33) 
In men     
Cardiovascular death  
  <120/<70 154 49,113 314 1.09 (0.92–1.28) 
  120–129/70–79 966 398,810 242 0.99 (0.92–1.07) 
  130–139/80–89 1,925 831,251 232 1.00 (reference) 
  140–149/90–99 1,369 434,534 315 1.24 (1.16–1.33) 
  ≥150/≥100 965 185,549 520 1.67 (1.54–1.80) 
MI 
  <120/<70 142 52,111 272 1.04 (0.88–1.23) 
  120–129/70–79 1,069 412,720 259 1.06 (0.99–1.15) 
  130–139/80–89 2,011 859,099 234 1.00 (reference) 
  140–149/90–99 1,076 455,901 236 1.00 (0.93–1.08) 
  ≥150/≥100 537 202,387 265 1.08 (0.98–1.19) 
Stroke 
  <120/<70 353 50,765 695 0.71 (0.64–0.79) 
  120–129/70–79 3,147 400,140 786 0.91 (0.87–0.94) 
  130–139/80–89 6,880 827,989 831 1.00 (reference) 
  140–149/90–99 4,329 434,348 997 1.13 (1.09–1.18) 
  ≥150/≥100 2,559 189,270 1,352 1.35 (1.29–1.41) 
Heart failure 
  <120/<70 206 51,791 398 1.51 (1.31–1.75) 
  120–129/70–79 1,224 412,314 297 1.23 (1.14–1.32) 
  130–139/80–89 2,025 859,889 235 1.00 (reference) 
  140–149/90–99 1,259 454,874 277 1.12 (1.04–1.20) 
  ≥150/≥100 677 201,792 335 1.23 (1.13–1.34) 
Cardiovascular death or MI or stroke or heart failure 
  <120/<70 796 48,377 1,645 0.95 (0.88–1.02) 
  120–129/70–79 5,912 384,330 1,538 1.00 (0.96–1.03) 
  130–139/80–89 11,842 800,222 1,480 1.00 (reference) 
  140–149/90–99 7,300 417,784 1,747 1.21 (1.09–1.16) 
  ≥150/≥100 4,230 179,862 2,352 1.34 (1.30–1.39) 
In women     
Cardiovascular death  
  <120/<70 149 143,133 104 0.99 (0.84–1.17) 
  120–129/70–79 998 625,053 160 0.98 (0.91–1.06) 
  130–139/80–89 1,805 932,392 194 1.00 (reference) 
  140–149/90–99 1,247 459,541 271 1.17 (1.09–1.26) 
  ≥150/≥100 979 203,961 480 1.57 (1.45–1.70) 
MI 
  <120/<70 127 145,201 87 0.88 (0.73–1.06) 
  120–129/70–79 799 635,664 126 1.01 (0.93–1.10) 
  130–139/80–89 1,281 951,661 135 1.00 (reference) 
  140–149/90–99 759 473,171 160 1.09 (1.00–1.20) 
  ≥150/≥100 448 214,805 209 1.26 (1.13–1.40) 
Stroke 
  <120/<70 558 142,857 391 0.64 (0.58–0.69) 
  120–129/70–79 4,045 616,131 657 0.85 (0.82–0.89) 
  130–139/80–89 7,604 912,815 833 1.00 (reference) 
  140–149/90–99 4,614 448,726 1,028 1.13 (1.09–1.17) 
  ≥150/≥100 2,626 200,683 1,309 1.25 (1.20–1.31) 
Heart failure 
  <120/<70 372 144,024 258 1.23 (1.11–1.38) 
  120–129/70–79 1,966 629,703 312 1.08 (1.02–1.15) 
  130–139/80–89 3,064 942,440 325 1.00 (reference) 
  140–149/90–99 1,642 468,561 350 0.96 (0.91–1.02) 
  ≥150/≥100 956 212,124 451 1.07 (0.99–1.15) 
Cardiovascular death or MI or stroke or heart failure 
  <120/<70 1,143 139,661 818 0.83 (0.78–0.88) 
  120–129/70–79 7,288 599,066 1,217 0.93 (0.90–0.96) 
  130–139/80–89 12,784 885,150 1,444 1.00 (reference) 
  140–149/90–99 7,569 432,936 1,748 1.09 (1.06–1.12) 
  ≥150/≥100 4,493 190,526 2,358 1.26 (1.21–1.30) 
 
Major cardiovascular event was defined as a composite of cardiovascular death, myocardial infarction, stroke, or heart failure. 
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
diabetes mellitus, medication (aspirin or statin), and antihypertensive medication. CI, confidence interval; HR, hazard ratio; and MI, myocardial 
infarction. 
Table S5. Incidences of Major Cardiovascular Events including Heart Failure According to Blood Pressure Level in Treated 
Hypertensive Patients without baseline heart failure. 
Blood pressure (mmHg) Events (n) Person-years Incidence  
(events/100,000 person-years) 
Adjusted HR (95% CI) 
In total population     
Cardiovascular death  
  <120/<70 157 47,921 328 1.39 (1.18–1.64) 
  120–129/70–79 997 427,274 233 1.05 (0.98–1.14) 
  130–139/80–89 1,919 878,877 218 1.00 (reference) 
  140–149/90–99 1,369 469,968 291 1.19 (1.11–1.28) 
  ≥150/≥100 1,022 211,504 483 1.58 (1.46–1.70) 
MI 
  <120/<70 105 49,832 211 1.10 (0.91–1.35) 
  120–129/70–79 895 438,111 204 1.10 (1.01–1.19) 
  130–139/80–89 1,674 902,028 186 1.00 (reference) 
  140–149/90–99 931 487,955 191 0.99 (0.92–1.08) 
  ≥150/≥100 545 225,351 242 1.18 (1.07–1.30) 
Stroke 
  <120/<70 346 48,525 713 0.79 (0.71–0.88) 
  120–129/70–79 3,296 424,112 777 0.90 (0.86–0.94) 
  130–139/80–89 7,336 868,068 845 1.00 (reference) 
  140–149/90–99 4,625 465,180 994 1.11 (1.07–1.15) 
  ≥150/≥100 2,715 211,700 1,282 1.26 (1.21–1.32) 
Heart failure 
  <120/<70 244 49,201 496 1.63 (1.43–1.86) 
  120–129/70–79 1,541 435,307 354 1.20 (1.12–1.28) 
  130–139/80–89 2,608 898,217 290 1.00 (reference) 
  140–149/90–99 1,581 485,072 326 1.05 (0.99–1.12) 
  ≥150/≥100 915 223,739 409 1.16 (1.07–1.25) 
Cardiovascular death or MI or stroke or heart failure 
  <120/<70 795 46,140 1,723 1.09 (1.01-1.17) 
  120–129/70–79 6,249 408,803 1,529 1.00 (0.97-1.04) 
  130–139/80–89 12,540 841,436 1,490 1.00 (reference) 
  140–149/90–99 7,783 449,098 1,733 1.09 (1.06-1.12) 
  ≥150/≥100 4,672 201,614 2,317 1.28 (1.24-1.32) 
In men     
Cardiovascular death  
  <120/<70 84 15,274 550 1.55 (1.24–1.94) 
  120–129/70–79 468 168,214 278 1.05 (0.94–1.17) 
  130–139/80–89 953 399,418 239 1.00 (reference) 
  140–149/90–99 686 215,834 318 1.23 (1.12–1.36) 
  ≥150/≥100 469 93,290 503 1.60 (1.43–1.79) 
MI 
  <120/<70 69 16,374 421 1.41 (1.11–1.81) 
  120–129/70–79 519 173,870 298 1.15 (1.03–1.28) 
  130–139/80–89 998 412,749 242 1.00 (reference) 
  140–149/90–99 548 226,496 242 1.00 (0.90–1.11) 
  ≥150/≥100 290 101,155 287 1.14 (1.00–1.30) 
Stroke 
  <120/<70 142 15,929 891 0.79 (0.66–0.93) 
  120–129/70–79 1,461 168,548 867 0.93 (0.88–0.98) 
  130–139/80–89 3,435 397,784 864 1.00 (reference) 
  140–149/90–99 2,171 216,032 1.005 1.11 (1.05–1.17) 
  ≥150/≥100 1,254 95,087 1,319 1.29 (1.21–1.38) 
Heart failure 
  <120/<70 100 16,277 614 2.01 (1.63–2.47) 
  120–129/70–79 582 173,834 335 1.28 (1.15–1.42) 
  130–139/80–89 1,014 413,221 245 1.00 (reference) 
  140–149/90–99 665 226,034 294 1.16 (1.05–1.28) 
  ≥150/≥100 366 100,819 363 1.30 (1.15–1.47) 
Cardiovascular death or MI or stroke or heart failure 
  <120/<70 367 14,740 2,490 1.23 (1.10-1.37) 
  120–129/70–79 2,809 161,090 1,744 1.04 (1.00-1.09) 
  130–139/80–89 5,911 384,686 1,537 1.00 (reference) 
  140–149/90–99 3,704 208,065 1,780 1.11 (1.07-1.16) 
  ≥150/≥100 2,144 90,364 2,373 1.33 (1.26-1.40) 
In women     
Cardiovascular death  
  <120/<70 73 32,646 224 1.28 (1.01–1.63) 
  120–129/70–79 529 259,059 204 1.06 (0.96–1.18) 
  130–139/80–89 966 479,459 201 1.00 (reference) 
  140–149/90–99 683 254,134 269 1.15 (1.05–1.27) 
  ≥150/≥100 553 118,214 468 1.56 (1.40–1.73) 
MI 
  <120/<70 36 33,457 108 0.81 (0.58–1.14) 
  120–129/70–79 376 264,240 142 1.05 (0.92–1.19) 
  130–139/80–89 676 489,279 138 1.00 (reference) 
  140–149/90–99 383 261,459 146 0.98 (0.87–1.11) 
  ≥150/≥100 255 124,195 205 1.21 (1.05–1.40) 
Stroke 
  <120/<70 204 32,595 626 0.78 (0.68–0.90) 
  120–129/70–79 1,835 255,564 718 0.88 (0.83–0.93) 
  130–139/80–89 3,901 470,283 830 1.00 (reference) 
  140–149/90–99 2,454 249,148 985 1.10 (1.05–1.16) 
  ≥150/≥100 1,461 116,613 1,253 1.23 (1.16–1.31) 
Heart failure 
  <120/<70 144 32,923 437 1.47 (1.24–1.75) 
  120–129/70–79 959 261,472 367 1.16 (1.07–1.25) 
  130–139/80–89 1,594 484,995 329 1.00 (reference) 
  140–149/90–99 916 259,038 354 0.98 (0.91–1.07) 
  ≥150/≥100 549 122,919 447 1.07 (0.97–1.18) 
Cardiovascular death or MI or stroke or heart failure 
  <120/<70 428 31,400 1,363 1.00 (0.91-1.11) 
  120–129/70–79 3,440 247,713 1,389 0.98 (0.94-1.02) 
  130–139/80–89 6,629 456,750 1,451 1.00 (reference) 
  140–149/90–99 4,079 241,032 1,692 1.07 (1.03-1.11) 
  ≥150/≥100 2,528 111,250 2,272 1.23 (1.18-1.29) 
 
Major cardiovascular event was defined as a composite of cardiovascular death, myocardial infarction, stroke, or heart failure. 
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 




Table S6. Incidences of Major Cardiovascular Events According to Blood Pressure Level and Sex in Patients with <50 Years.  



















Adjusted HR (95% 
CI) 
In men         
All-cause death         
  <120/<70 41 15,892 258 1.09 (0.79–1.51) 9 2,535 355 1.34 (0.68–2.61) 
  120–129/70–79 251 126,818 198 0.90 (0.77–1.04) 99 35,702 277 1.10 (0.87–1.40) 
  130–139/80–89 562 252,602 222 1.00 (reference) 227 94,297 241 1.00 (reference) 
  140–149/90–99 364 120,294 303 1.31 (1.15–1.50) 179 47,746 375 1.53 (1.25–1.86) 
  ≥150/≥100 220 46,370 474 1.98 (1.69–2.32) 92 17,996 511 2.01 (1.57–2.57) 
Cardiovascular 
death 
        
  <120/<70 10 15,892 63 1.20 (0.62–2.32) 3 2,535 118 1.61 (0.50–5.19) 
  120–129/70–79 42 126,818 33 0.69 (0.49–0.99) 25 35,702 70 1.08 (0.67–1.74) 
  130–139/80–89 119 252,602 47 1.00 (reference) 57 94,297 60 1.00 (reference) 
  140–149/90–99 103 120,294 86 1.80 (1.38–2.35) 49 47,746 103 1.70 (1.16–2.49) 
  ≥150/≥100 72 46,370 155 3.19 (2.37–4.29) 34 17,996 189 2.96 (1.92–4.57) 
MI         
  <120/<70 15 16,017 94  0.69 (0.41–1.15) 6 2,556 235 1.20 (0.53–2.72) 
  120–129/70–79 187 126,666 148  1.00 (0.84–1.19) 81 35,547 228 1.24 (0.95–1.63) 
  130–139/80–89 396 252,828 157  1.00 (reference) 162 94,393 172 1.00 (reference) 
  140–149/90–99 193 121,096 159  1.03 (0.87–1.22) 81 48,191 168 1.00 (0.77–1.31) 
  ≥150/≥100 82 47,191 174  1.17 (0.92–1.49) 31 18,327 169 1.02 (0.69–1.50) 
Stroke         
  <120/<70 22 15,996 138  0.51 (0.33–0.78) 5 2,563 195 0.55 (0.23–1.32) 
  120–129/70–79 279 126,144 221  0.82 (0.71–0.95) 95 35,547 267 0.7890.62–0.99) 
  130–139/80–89 709 250,786 283  1.00 (reference) 308 93,412 330 1.00 (reference) 
  140–149/90–99 432 119,510 361  1.27 (1.12–1.43) 192 47,474 404 1.25 (1.04–1.49) 
  ≥150/≥100 307 45,970 668  2.37 (2.07–2.72) 121 17,855 678 2.12 (0.71–2.63) 
Cardiovascular 
death or MI or 
stroke 
        
  <120/<70 46 15,850 290  0.65 (0.49–0.88) 14 2,499 560 0.93 (0.55–1.59) 
  120–129/70–79 493 124,767 395  0.88 (0.79–0.97) 195 34,926 558 0.99 (0.84–1.17) 
  130–139/80–89 1173 248,000 473  1.00 (reference) 499 92,299 541 1.00 (reference) 
  140–149/90–99 675 118,113 571  1.20 (1.10–1.32) 297 46,884 633 1.19 (1.03–1.37) 
  ≥150/≥100 426 45,330 940  2.02 (1.80–2.25) 170 17,620 965 1.82 (1.52–2.17) 
In women         
All-cause death         
  <120/<70 59 57,401 103 1.01 (0.73–1.39) 14 5,606 250 2.07 (1.14–3.77) 
  120–129/70–79 113 131,235 86 0.80 (0.62–1.02) 31 34,258 90 0.78 (0.51–1.19) 
  130–139/80–89 159 139,311 114 1.00 (reference) 68 59,839 114 1.00 (reference) 
  140–149/90–99 76 54,561 139 1.19 (0.91–1.57) 39 26,537 147 1.30 (0.87–1.92) 
  ≥150/≥100 45 19,459 231 1.94 (1.39–2.70) 29 9,946 292 2.53 (1.64–3.92) 
Cardiovascular         
death 
  <120/<70 9 57,401 16 0.59 (0.27–1.27) 3 5,606 54 1.63 (0.46–5.77) 
  120–129/70–79 19 131,235 14 0.57 (0.32–1.00) 8 34,258 23 0.78 (0.34–1.82) 
  130–139/80–89 35 139,311 25 1.00 (reference) 17 59,839 28 1.00 (reference) 
  140–149/90–99 19 54,561 35 1.40 (0.80–2.44) 8 26,537 30 1.09 (0.47–2.53) 
  ≥150/≥100 21 19,459 108 4.30 (2.50–7.41) 10 9,946 101 3.45 (1.57–7.56) 
MI         
  <120/<70 16 57,594 28 0.88 (0.50–1.57) 0 5,663 0 0 
  120–129/70–79 61 131,402 46 1.18 (0.83–1.69) 17 34,284 50 1.02 (0.56–1.86) 
  130–139/80–89 63 139,570 45 1.00 (reference) 30 59,966 50 1.00 (reference) 
  140–149/90–99 36 54,687 66 1.40 (0.93–2.10) 17 26,593 64 1.26 (0.70–2.29) 
  ≥150/≥100 11 19,584 56 1.17 (0.61–2.21) 5 10,048 50 0.96 (0.37–2.47) 
Stroke         
  <120/<70 60 57,398 105 0.48 (0.36–0.64) 8 5,639 142 0.57 (0.28–1.18) 
  120–129/70–79 272 130,162 209 0.86 (0.73–1.01) 73 33,996 215 0.85 (0.64–1.12) 
  130–139/80–89 363 137,976 263 1.00 (reference) 150 59,251 253 1.00 (reference) 
  140–149/90–99 198 53,763 368 1.37 (1.16–1.64) 84 26,262 320 1.27 (0.97–1.66) 
  ≥150/≥100 111 19,078 582 2.16 (1.75–2.68) 52 9,779 532 2.09 (1.52–2.87) 
Cardiovascular 
death or MI or 
stroke 
        
  <120/<70 83 57,265 145 0.56 (0.44–0.71) 11 5,617 196 0.64 (0.34–1.18) 
  120–129/70–79 341 129,778 263 0.90 (0.78–1.04) 92 33,894 271 0.85 (0.66–1.09) 
  130–139/80–89 439 137,489 319 1.00 (reference) 188 59,033 318 1.00 (reference) 
  140–149/90–99 236 53,548 441 0.35 (1.15–1.58) 103 26,134 394 1.24 (0.98–1.58) 
  ≥150/≥100 130 18,945 686 2.09 (1.72–2.54) 62 9,701 639 1.99 (1.49–2.65) 
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
diabetes mellitus, medication (aspirin or statin), and antihypertensive medication. CI, confidence interval; HR, hazard ratio; and MI, myocardial 
infarction. 
 
Table S7. Incidences of Major Cardiovascular Events According to Blood Pressure Level and Sex in Patients with 50-59 Years.  



















Adjusted HR (95% 
CI) 
In men         
All-cause death         
  <120/<70 104 12870 808  1.24 (1.01–1.52) 49 4,413 1,110 1.81 (1.35–2.43) 
  120–129/70–79 632 115607 547  0.95 (0.87–1.05) 283 54,269 521 0.95 (0.83–1.09) 
  130–139/80–89 1425 261264 545  1.00 (reference) 702 133,517 526 1.00 (reference) 
  140–149/90–99 875 129946 673  1.23 (1.13–1.34) 434 67,436 644 1.22 (1.08–1.37) 
  ≥150/≥100 533 47825 1114  1.88 (1.70–2.07) 253 24,499 1,033 1.82 (1.57–2.10) 
Cardiovascular 
death 
        
  <120/<70 21 12870 163  1.30 (0.83–2.03) 14 4,413 317 2.74 (1.57–4.79) 
  120–129/70–79 129  115607 112  0.99 (0.80–1.21) 67 54,269 123 1.21 (0.90–1.63) 
  130–139/80–89 281  261264 108  1.00 (reference) 128 133,517 96 1.00 (reference) 
  140–149/90–99 166  129946 128  1.21 (0.99–1.46) 81 67,436 120 1.28 (0.97–1.69) 
  ≥150/≥100 124  47825 259  2.26 (1.83–2.80) 57 24,499 233 2.43 (1.78–3.32) 
MI         
  <120/<70 39 13174 296  1.07 (0.77–1.48) 19 4,541 418 1.51 (0.95–2.41) 
  120–129/70–79 306 116447 263  1.00 (0.87–1.150 152 54,487 279 1.10 (0.91–1.34) 
  130–139/80–89 650 263660 247  1.00 (reference) 317 134,617 235 1.00 (reference) 
  140–149/90–99 289 132452 218  0.93 (0.81–1.06) 152 68,628 221 0.99 (0.81–1.20) 
  ≥150/≥100 118 50051 236  1.00 (0.82–1.22) 62 25,584 242 1.09 (0.83–1.43) 
Stroke         
  <120/<70 73 12973 563  0.72 (0.57–0.91) 25 4,479 558 0.72 (0.48–1.08) 
  120–129/70–79 703 114160 616  0.90 (0.82–0.98) 328 53,447 614 0.92 (0.81–1.04) 
  130–139/80–89 1645 257026 640  1.00 (reference) 826 131,305 629 1.00 (reference) 
  140–149/90–99 957 127944 748  1.19 (1.10–1.29) 474 66,488 713 1.15 (1.03–1.29) 
  ≥150/≥100 514 47421 1084  1.66 (1.50–1.83) 240 24,367 985 1.53 (1.32–1.77) 
Cardiovascular 
death or MI or 
stroke 
        
  <120/<70 123 12709 968  0.83 (0.69–1.00) 51 4,347 1,173 1.02(0.77–1.35) 
  120–129/70–79 1078 111886 963  0.93 (0.86–0.99) 521 52,342 995 0.99(0.89–1.10) 
  130–139/80–89 2455 252261 973  1.00 (reference) 1,215 129,136 941 1.00 (reference) 
  140–149/90–99 1324 125810 1052  1.11 (1.04–1.18) 660 65,464 1,008 1.10(1.00–1.21) 
  ≥150/≥100 680 46509 1462  1.49 (1.37–1.62) 321 23,956 1,340 1.42(1.25–1.61) 
In women         
All-cause death         
  <120/<70 86 46662 184  0.99 (0.79–1.24) 30 11,817 254 1.27 (0.87–1.85) 
  120–129/70–79 408 213945 191  0.99 (0.87–1.12) 181 88,571 204 1.03 (0.86–1.24) 
  130–139/80–89 599 308523 194  1.00 (reference) 308 156,533 197 1.00 (reference) 
  140–149/90–99 326 132175 247  1.25 (1.10–1.44) 177 72,378 245 1.24 (1.03–1.49) 
  ≥150/≥100 173 46328 373  1.87 (1.58–2.22) 100 25,984 385 1.90 (1.51–2.38) 
Cardiovascular         
death 
  <120/<70 18 46662 39  0.95 (0.58–1.56) 8 11,817 68 1.47 (0.70–3.01) 
  120–129/70–79 81 213945 38  0.90 (0.68–1.19) 36 88,571 41 0.91 (0.60–1.35) 
  130–139/80–89 131 308523 42  1.00 (reference) 70 156,533 45 1.00 (reference) 
  140–149/90–99 78 132175 59  1.38 (1.04–1.82) 51 72,378 70 1.60 (1.11–2.29) 
  ≥150/≥100 54 46328 117  2.68 (1.95–3.69) 35 25,984 135 3.00 (1.99–4.52) 
MI         
  <120/<70 47 46691 101  1.15 (0.84–1.57) 7 11,879 59 0.67 (0.31–1.43) 
  120–129/70–79 198 214498 92  1.03 (0.86–1.24) 74 88,890 83 1.00 (0.75–1.33) 
  130–139/80–89 273 309267 88  1.00 (reference) 127 157,015 81 1.00 (reference) 
  140–149/90–99 143 132754 108  1.21 (0.99–1.48) 71 72,653 98 1.20 (0.90–1.60) 
  ≥150/≥100 58 46822 124  1.34 (1.01–1.78) 27 26,295 103 1.16 (0.77–1.77) 
Stroke         
  <120/<70 139 46197 301  0.60 (0.51–0.72) 43 11,687 368 0.73 (0.53–0.99) 
  120–129/70–79 822 210670 390  0.77 (0.71–0.84) 350 87,157 402 0.80 (0.71–0.91) 
  130–139/80–89 1515 301458 503  1.00 (reference) 754 153,150 492 1.00 (reference) 
  140–149/90–99 736 128912 571  1.12 (1.03–1.22) 397 70,648 562 1.12 (1.00–1.27) 
  ≥150/≥100 302 45276 667  1.27 (1.12–1.44) 155 25,495 608 1.17 (0.99–1.40) 
Cardiovascular 
death or MI or 
stroke 
        
  <120/<70 198 45827 432  0.71 (0.61–0.82) 57 11,618 491 0.79(0.60–1.03) 
  120–129/70–79 1047 209455 500  0.81 (0.75–0.87) 438 86,692 505 0.83(0.74–0.93) 
  130–139/80–89 1845 299554 616  1.00 (reference) 913 152,345 599 1.00 (reference) 
  140–149/90–99 904 127897 707  1.13 (1.05–1.23) 485 70,084 692 1.14(1.02–1.27) 
  ≥150/≥100 381 44878 849  1.32 (1.18–1.47) 197 25,277 779 1.23(1.06–1.44) 
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
diabetes mellitus, medication (aspirin or statin), and antihypertensive medication. CI, confidence interval; HR, hazard ratio; and MI, myocardial 
infarction. 
 
Table S8. Incidences of Major Cardiovascular Events According to Blood Pressure Level and Sex in Patients with 60-69 Years.  



















Adjusted HR (95% 
CI) 
In men         
All-cause death         
  <120/<70 287 14,230 2,017 1.24 (1.10–1.40) 128 5,912 2,165 1.31 (1.09–1.57) 
  120–129/70–79 1,707 113,987 1,498 1.02 (0.96–1.08) 826 58,090 1,422 0.97 (0.89–1.06) 
  130–139/80–89 3,239 231,183 1,401 1.00 (reference) 1,743 125,673 1,387 1.00 (reference) 
  140–149/90–99 1,999 129,409 1,545 1.08 (1.02–1.14) 1,099 71,115 1,545 1.08 (1.00–1.17) 
  ≥150/≥100 1,306 58,936 2,216 1.48 (1.38–1.58) 698 32,865 2,124 1.46 (1.33–1.59) 
Cardiovascular 
death 
        
  <120/<70 66 14,230 464 1.42 (1.10–1.83) 41 5,912 694 2.11 (1.52–2.93) 
  120–129/70–79 366 113,987 321 1.10 (0.96–1.25) 198 58,090 341 1.17 (0.98–1.39) 
  130–139/80–89 644 231,183 279 1.00 (reference) 347 125,673 276 1.00 (reference) 
  140–149/90–99 450 129,409 348 1.23 (1.09–1.39) 253 71,115 356 1.25 (1.07–1.48) 
  ≥150/≥100 303 58,936 514 1.76 (1.54–2.02) 166 32,865 505 1.78 (1.47–2.14) 
MI         
  <120/<70 48 15,216 315 0.93 (0.70–1.26) 20 6,306 317 0.96 (0.61–1.51) 
  120–129/70–79 399 118,709 336 1.11 (0.98–1.25) 209 60,093 348 1.18 (1.00–1.40) 
  130–139/80–89 690 240,529 287 1.00 (reference) 363 130,478 278 1.00 (reference) 
  140–149/90–99 397 136,089 292 1.04 (0.92–1.18) 207 74,781 277 1.00 (0.84–1.19) 
  ≥150/≥100 204 64,278 317 1.14 (0.97–1.33) 118 35,542 332 1.22 (0.99–1.50) 
Stroke         
  <120/<70 142 14,621 971 0.74 (0.63–0.88) 71 5,997 1,184 0.95 (0.75–1.20) 
  120–129/70–79 1,276 113,328 1,126 0.91 (0.85–0.98) 647 57,626 1,123 0.96 (0.87–1.05) 
  130–139/80–89 2,715 227,902 1,191 1.00 (reference) 1,409 124,238 1,134 1.00 (reference) 
  140–149/90–99 1,711 127,775 1,339 1.12 (1.06–1.19) 896 70,468 1,271 1.11 (1.02–1.21) 
  ≥150/≥100 985 59,214 1,663 1.36 (1.26–1.46) 532 32,969 1,614 1.38 (1.25–1.53) 
Cardiovascular 
death or MI or 
stroke 
        
  <120/<70 228 14,165 1,610 0.86 (0.75–0.98) 118 5,767 2,046 1.15 (0.95–1.38) 
  120–129/70–79 1,867 110,199 1,694 0.98 (0.93–1.04) 958 56,015 1,710 1.04 (0.96–1.12) 
  130–139/80–89 3,685 222,532 1,656 1.00 (reference) 1,920 121,559 1,579 1.00 (reference) 
  140–149/90–99 2,296 124,731 1,841 1.11 (1.06–1.17) 1,212 68,867 1,760 1.10 (1.03–1.19) 
  ≥150/≥100 1,312 57,376 2,287 1.36 (1.27–1.45) 722 31,962 2,259 1.40 (1.29–1.53) 
In women         
All-cause death         
  <120/<70 238 31,624 753 1.29 (1.12–1.47) 99 11,586 854 1.45 (1.18–1.79) 
  120–129/70–79 1,092 200,081 546 0.94 (0.87–1.01) 526 94,695 555 0.97 (0.87–1.08) 
  130–139/80–89 1,921 329,033 584 1.00 (reference) 1,007 175,652 573 1.00 (reference) 
  140–149/90–99 1,184 175,256 676 1.11 (1.04–1.20) 661 99,112 667 1.12 (1.02–1.24) 
  ≥150/≥100 752 78,399 959 1.54 (1.41–1.68) 443 46,895 945 1.55 (1.38–1.73) 
Cardiovascular         
death 
  <120/<70 45 31,624 142 0.97 (0.72–1.33) 25 11,586 216 1.45 (0.96–2.19) 
  120–129/70–79 273 200,081 136 0.94 (0.81–1.09) 145 94,695 153 1.05 (0.85–1.28) 
  130–139/80–89 482 329,033 146 1.00 (reference) 257 175,652 146 1.00 (reference) 
  140–149/90–99 352 175,256 201 1.32 (1.15–1.51) 185 99,112 187 1.22 (1.01–1.48) 
  ≥150/≥100 220 78,399 281 1.79 (1.52–2.10) 125 46,895 267 1.70 (1.37–2.11) 
MI         
  <120/<70 53 32,255 164 1.00 (0.75–1.32) 26 11,803 220 1.28 (0.86–1.92) 
  120–129/70–79 340 202,214 168 1.02 (0.89–1.17) 187 95,565 196 1.17 (0.97–1.40) 
  130–139/80–89 550 333,540 165 1.00 (reference) 297 177,901 167 1.00 (reference) 
  140–149/90–99 338 178,253 190 1.13 (0.99–1.29) 168 100,880 167 0.98 (0.81–1.18) 
  ≥150/≥100 194 80,538 241 1.40 (1.19–1.65) 118 48,189 245 1.40 (1.13–1.73) 
Stroke         
  <120/<70 232 31,272 742 0.73 (0.64–0.84) 92 11,448 804 0.82 (0.66–1.01) 
  120–129/70–79 1,694 194,071 873 0.88 (0.83–0.93) 781 92,085 848 0.90 (0.83–0.98) 
  130–139/80–89 3,138 317,384 989 1.00 (reference) 1,589 170,167 934 1.00 (reference) 
  140–149/90–99 1,973 168,030 1,174 1.17 (1.10–1.24) 1,054 95,681 1,102 1.16 (1.07–1.26) 
  ≥150/≥100 1,045 75,015 1,393 1.35 (1.26–1.45) 598 45,172 1,324 1.36 (1.24–1.50) 
Cardiovascular 
death or MI or 
stroke 
        
  <120/<70 316 30,830 1,025 0.82 (0.73–0.92) 137 11,204 1,223 0.99 (0.83–1.18) 
  120–129/70–79 2,154 191,687 1,124 0.91 (0.86–0.96) 1,044 90,805 1,150 0.97 (0.90–1.04) 
  130–139/80–89 3,856 313,729 1,229 1.00 (reference) 1,981 168,241 1,177 1.00 (reference) 
  140–149/90–99 2,436 165,654 1,471 1.18 (1.12–1.24) 1,292 94,600 1,366 1.14 (1.06–1.22) 
  ≥150/≥100 1,307 73,550 1,777 1.39 (1.30–1.48) 757 44,334 1,707 1.39 (1.28–1.51) 
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
diabetes mellitus, medication (aspirin or statin), and antihypertensive medication. CI, confidence interval; HR, hazard ratio; and MI, myocardial 
infarction. 
 
Table S9. Incidences of Major Cardiovascular Events According to Blood Pressure Level and Sex in Patients with ≥70 Years.  



















Adjusted HR (95% 
CI) 
In men         
All-cause death         
  <120/<70 530 9,028 5,871 1.22 (1.12–1.34) 238 4,079 5,835 1.28 (1.12–1.46) 
  120–129/70–79 2,690 56,128 4,793 1.06 (1.01–1.11) 1,219 27,964 4,359 1.01 (0.95–1.09) 
  130–139/80–89 4,630 104,631 4,425 1.00 (reference) 2,351 56,247 4,180 1.00 (reference) 
  140–149/90–99 3,092 63,798 4,847 1.09 (1.05–1.15) 1,585 34,839 4,549 1.08 (1.02–1.15) 
  ≥150/≥100 2,101 36,318 5,785 1.24 (1.18–1.31) 1,054 20,292 5,194 1.16 (1.08–1.25) 
Cardiovascular 
death 
        
  <120/<70 123 9,028 1,362 1.24 (1.03–1.50) 73 4,079 1,790 1.69 (1.32–2.16) 
  120–129/70–79 594 56,128 1,058 1.01 (0.91–1.12) 276 27,964 987 1.01 (0.88–1.17) 
  130–139/80–89 1,082 104,631 1,034 1.00 (reference) 535 56,247 951 1.00 (reference) 
  140–149/90–99 757 63,798 1,187 1.14 (1.04–1.25) 359 34,839 1,030 1.08 (0.95–1.24) 
  ≥150/≥100 548 36,318 1,509 1.37 (1.23–1.51) 262 20,292 1,291 1.27 (1.09–1.47) 
MI         
  <120/<70 67 11,205 598 1.48 (1.14–1.91) 36 4,970 724 1.72 (1.21–2.45) 
  120–129/70–79 290 66,180 438 1.16 (1.00–1.34) 138 32,348 427 1.10 (0.89–1.36) 
  130–139/80–89 447 122,120 366 1.00 (reference) 240 64,505 372 1.00 (reference) 
  140–149/90–99 291 76,281 381 1.06 (0.91–1.23) 150 40,746 368 1.00 (0.81–1.22) 
  ≥150/≥100 184 45,627 403 1.11 (0.93–1.32) 103 24,579 419 1.12 (0.89–1.41) 
Stroke         
  <120/<70 181 10,465 1,730 0.79 (0.68–0.92) 77 4,768 1,615 0.78 (0.62–0.98) 
  120–129/70–79 1,207 60,611 1,991 0.94 (0.88–1.01) 559 29,947 1,867 0.94 (0.85–1.04) 
  130–139/80–89 2,306 110,329 2,090 1.00 (reference) 1,149 59,007 1,947 1.00 (reference) 
  140–149/90–99 1,545 67,763 2,280 1.10 (1.03–1.17) 763 36,842 2,071 1.06 (0.97–1.16) 
  ≥150/≥100 952 40,494 2,351 1.11 (1.03–1.20) 474 22,232 2,132 1.08 (0.97–1.20) 
Cardiovascular 
death or MI or 
stroke 
        
  <120/<70 317 9,740 3,255 0.99 (0.88–1.11) 160 4,325 3,699 1.14 (0.97–1.35) 
  120–129/70–79 1,754 57,705 3,040 0.98 (0.92–1.03) 830 28,500 2,912 0.96 (0.89–1.05) 
  130–139/80–89 3,228 105,674 3,055 1.00 (reference) 1,649 56,541 2,916 1.00 (reference) 
  140–149/90–99 2,144 64,549 3,322 1.09 (1.03–1.15) 1,066 35,365 3,014 1.03 (0.95–1.11) 
  ≥150/≥100 1,392 38,037 3,660 1.17 (1.10–1.25) 707 21,003 3,366 1.12 (1.03–1.23) 
In women         
All-cause death         
  <120/<70 492 15,542 3,166 1.23 (1.13–1.36) 233 7,243 3,217 1.30 (1.14–1.49) 
  120–129/70–79 2,923 110,013 2,657 1.07 (1.02–1.12) 1,493 56,851 2,626 1.09 (1.02–1.16) 
  130–139/80–89 4,916 193,574 2,540 1.00 (reference) 2,626 108,267 2,425 1.00 (reference) 
  140–149/90–99 3,283 116,477 2,819 1.08 (1.03–1.13) 1,851 67,451 2,744 1.10 (1.04–1.17) 
  ≥150/≥100 2,427 68,977 3,519 1.25 (1.19–1.31) 1,376 40,860 3,368 1.26 (1.18–1.34) 
Cardiovascular         
death 
  <120/<70 148 15,542 952 1.27 (1.07–1.50) 84 7,243 1,160 1.61 (1.28–2.01) 
  120–129/70–79 866 110,013 787 1.08 (0.99–1.17) 470 56,851 827 1.16 (1.04–1.30) 
  130–139/80–89 1,446 193,574 747 1.00 (reference) 772 108,267 713 1.00 (reference) 
  140–149/90–99 982 116,477 843 1.10 (1.01–1.19) 559 67,451 829 1.13 (1.01–1.26) 
  ≥150/≥100 808 68,977 1,171 1.40 (1.28–1.53) 448 40,860 1,096 1.39 (1.24–1.56) 
MI         
  <120/<70 44 17,441 252 0.82 (0.60–1.11) 20 8,115 246 0.82 (0.52–1.29) 
  120–129/70–79 343 119,765 286 0.96 (0.84–1.10) 176 61,892 284 0.9890.72–1.18) 
  130–139/80–89 619 209,488 295 1.00 (reference) 336 116,536 288 1.00 (reference) 
  140–149/90–99 371 127,984 290 0.97 (0.85–1.10) 197 73,684 267 0.91 (0.76–1.09) 
  ≥150/≥100 274 78,103 351 1.15 (0.99–1.32) 159 45,751 348 1.15 (0.95–1.39) 
Stroke         
  <120/<70 246 16,255 1,513 0.80 (0.70–0.91) 117 7,570 1,546 0.85 (0.71–1.03) 
  120–129/70–79 1,903 110,539 1,722 0.93 (0.88–0.98) 951 57,362 1,658 0.93 (0.86–1.01) 
  130–139/80–89 3,538 192,073 1,842 1.00 (reference) 1,906 107,792 1,768 1.00 (reference) 
  140–149/90–99 2,303 115,982 1,986 1.08 (1.02–1.14) 1,267 67,430 1,879 1.06 (0.99–1.14) 
  ≥150/≥100 1,523 70,080 2,173 1.16 (1.09–1.23) 856 41,493 2,063 1.15 (1.06–1.24) 
Cardiovascular 
death or MI or 
stroke 
        
  <120/<70 365 15,662 2,330 0.87 (0.78–0.97) 180 7,282 2,472 0.97 (0.83–1.13) 
  120–129/70–79 2,628 107,291 2,449 0.95 (0.91–1.00) 1,340 55,746 2,404 0.97 (0.91–1.03) 
  130–139/80–89 4,779 186,248 2,566 1.00 (reference) 2,578 104,785 2,460 1.00 (reference) 
  140–149/90–99 3,097 112,218 2,760 1.07 (1.02–1.12) 1,728 65,287 2,647 1.06 (1.00–1.13) 
  ≥150/≥100 2,163 66,813 3,237 1.21 (1.15–1.27) 1,215 39,768 3,055 1.19 (1.11–1.28) 
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
diabetes mellitus, medication (aspirin or statin), and antihypertensive medication. CI, confidence interval; HR, hazard ratio; and MI, myocardial 
infarction. 
 
Table S10. Incidences of Major Cardiovascular Events According to Blood Pressure Level and Sex among Treated Hypertensive Patients. 
Blood pressure (mmHg) Events (n) Person-years Incidence  
(events/100,000 person-years) 
Adjusted HR (95% CI) 
In men     
Cardiovascular death     
  <120/<70 131 16,939 773 1.94 (1.61–2.33) 
  120–129/70–79 566 176,025 322 1.10 (0.99–1.21) 
  130–139/80–89 1,067 409,734 260 1.00 (reference) 
  140–149/90–99 742 221,136 336 1.20 (1.09–1.32) 
  ≥150/≥100 521 95,652 545 1.60 (1.44–1.78) 
MI     
  <120/<70 81 18,373 441 1.35 (1.08–1.70) 
  120–129/70–79 580 182,475 318 1.15 (1.04–1.27) 
  130–139/80–89 1,082 423,992 255 1.00 (reference) 
  140–149/90–99 590 232,346 254 0.99 (0.90–1.10) 
  ≥150/≥100 314 104,032 302 1.13 (0.99–1.28) 
Stroke     
  <120/<70 178 17,808 1,000 0.82 (0.71–0.96) 
  120–129/70–79 1,629 176,567 923 0.93 (0.88–0.99) 
  130–139/80–89 3,692 407,960 905 1.00 (reference) 
  140–149/90–99 2,325 221,272 1,051 1.11 (1.06–1.17) 
  ≥150/≥100 1,367 97,423 1,403 1.32 (1.24–1.40) 
Cardiovascular death or MI or stroke 
  <120/<70 343 16,939 2,025 1.12 (1.01–1.25) 
  120–129/70–79 2,504 171,783 1,458 1.00 (0.96–1.05) 
  130–139/80–89 5,283 399,536 1,322 1.00 (reference) 
  140–149/90–99 3,235 216,580 1,494 1.09 (1.04–1.14) 
  ≥150/≥100 1,920 94,541 2,031 1.32 (1.25–1.39) 
In women     
Cardiovascular death     
  <120/<70 120 36,251 331 1.57 (1.30–1.90) 
  120–129/70–79 659 274,375 240 1.11 (1.01–1.22) 
  130–139/80–89 1,116 500,291 223 1.00 (reference) 
  140–149/90–99 803 265,477 302 1.18 (1.08–1.29) 
  ≥150/≥100 618 123,776 499 1.53 (1.39–1.69) 
MI     
  <120/<70 53 37,460 141 0.92 (0.70–1.22) 
  120–129/70–79 454 280,631 162 1.06 (0.94–1.18) 
  130–139/80–89 790 511,418 154 1.00 (reference) 
  140–149/90–99 453 273,809 165 0.99 (0.88–1..11) 
  ≥150/≥100 309 130,282 237 1.25 (1.09–1.42) 
Stroke     
  <120/<70 260 36,344 715 0.81 (0.71–0.91) 
  120–129/70–79 2,155 270,600 796 0.89 (0.85–0.94) 
  130–139/80–89 4,399 490,359 897 1.00 (reference) 
  140–149/90–99 2,802 260,021 1,078 1.12 (1.06–1.17) 
  ≥150/≥100 1,661 121,939 1,362 1.24 (1.17–1.31) 
Cardiovascular death or MI or stroke 
  <120/<70 385 35,721 1,078 0.93 (0.84–1.03) 
  120–129/70–79 2,914 267,137 1,091 0.94 (0.90–0.98) 
  130–139/80–89 5,660 484,404 1,168 1.00 (reference) 
  140–149/90–99 3,608 256,106 1,409 1.11 (1.06–1.16) 
  ≥150/≥100 2,231 119,080 1,874 1.28 (1.22–1.34) 
HR was adjusted for age, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
diabetes mellitus, and medication (aspirin or statin). CI, confidence interval; HR, hazard ratio; and MI, myocardial infarction. 
 
Table S11. Incidences of Major Cardiovascular Events According to Blood Pressure Level in Patients without antihypertensive 
medications. 
Blood pressure (mmHg) Events (n) Person-years Incidence  
(events/100,000 person-years) 
Adjusted HR (95% CI) 
In total population     
All-cause death     
  <120/<70 1,037  150,058  691  1.09 (1.02-1.16) 
  120–129/70–79 5,158  617,412  835  1.00 (0.97-1.04) 
  130–139/80–89 8,419  910,095  925  1.00 (reference) 
  140–149/90–99 5,174  435,302  1,189  1.11 (1.07-1.15) 
  ≥150/≥100 3,512  183,183  1,917  1.44 (1.38-1.49) 
Cardiovascular death     
  <120/<70 189  150,058  126  0.86 (0.74-1.00) 
  120–129/70–79 1,145  617,412  185  0.93 (0.86-1.00) 
  130–139/80–89 2,037  910,095  224  1.00 (reference) 
  140–149/90–99 1,362  435,302  313  1.19 (1.11-1.28) 
  ≥150/≥100 1,011  183,183  552  1.65 (1.53-1.78) 
MI     
  <120/<70 195  153,759  127  0.82 (0.71-0.95) 
  120–129/70–79 1,090  632,773  172  0.94 (0.87-1.02) 
  130–139/80–89 1,816  935,592  194  1.00 (reference) 
  140–149/90–99 1,015  453,442  224  1.10 (1.01-1.18) 
  ≥150/≥100 502  197,880  254  1.16 (1.05-1.28) 
Stroke     
  <120/<70 657  151,025  435  0.62 (0.58-0.68) 
  120–129/70–79 4,372  612,519  714  0.86 (0.83-0.89) 
  130–139/80–89 7,838  896,614  874  1.00 (reference) 
  140–149/90–99 4,728  428,386  1,104  1.17 (1.12-1.21) 
  ≥150/≥100 2,711  183,185  1,480  1.36 (1.30-1.42) 
Cardiovascular death or MI or stroke 
  <120/<70 948  149,387  635  0.68 (0.63-0.73) 
  120–129/70–79 5,944  603,847  984  0.88 (0.85-0.91) 
  130–139/80–89 10,517  881,545  1,193  1.00 (reference) 
  140–149/90–99 6,269  419,834  1,493  1.15 (1.12-1.19) 
  ≥150/≥100 3,640  177,816  2,047  1.37 (1.32-1.43) 
In Men     
All-cause death     
  <120/<70 538  35,080  1,534  1.17 (1.07-1.28) 
  120–129/70–79 2,853  236,514  1,206  1.06 (1.01-1.11) 
  130–139/80–89 4,833  439,945  1,099  1.00 (reference) 
  140–149/90–99 3,033  222,311  1,364  1.12 (1.07-1.17) 
  ≥150/≥100 2,063  93,796  2,199  1.48 (1.41-1.56) 
Cardiovascular death     
  <120/<70 89  35,080  254  0.91 (0.73-1.13) 
  120–129/70–79 565  236,514  239  0.97 (0.88-1.07) 
  130–139/80–89 1,059  439,945  241  1.00 (reference) 
  140–149/90–99 734  222,311  330  1.23 (1.12-1.35) 
  ≥150/≥100 526  93,796  561  1.69 (1.52-1.87) 
MI     
  <120/<70 88  37,238  236  0.89 (0.72-1.11) 
  120–129/70–79 602  245,525  245  0.99 (0.90-1.10) 
  130–139/80–89 1,101  455,145  242  1.00 (reference) 
  140–149/90–99 580  233,572  248  1.01 (0.92-1.12) 
  ≥150/≥100 274  103,115  266  1.04 (0.91-1.19) 
Stroke     
  <120/<70 240  36,247  662  0.69 (0.61-0.79) 
  120–129/70–79 1,836  237,676  772  0.90 (0.85-0.95) 
  130–139/80–89 3,683  438,082  841  1.00 (reference) 
  140–149/90–99 2,320  221,720  1,046  1.17 (1.11-1.23) 
  ≥150/≥100 1,391  95,676  1,454  1.42 (1.33-1.51) 
Cardiovascular death or MI or stroke 
  <120/<70 371  35,525  1,044  0.75 (0.67-0.83) 
  120–129/70–79 2,688  232,775  1,155  0.92 (0.88-0.96) 
  130–139/80–89 5,258  428,929  1,226  1.00 (reference) 
  140–149/90–99 3,204  216,622  1,479  1.14 (1.10-1.20) 
  ≥150/≥100 1,890  92,710  2,039  1.39 (1.32-1.47) 
In Women     
All-cause death     
  <120/<70 499  114,978  434  1.17 (1.07-1.29) 
  120–129/70–79 2,305  380,897  605  1.00 (0.95-1.06) 
  130–139/80–89 3,586  470,149  763  1.00 (reference) 
  140–149/90–99 2,141  212,990  1,005  1.08 (1.03-1.14) 
  ≥150/≥100 1,449  89,386  1,621  1.33 (1.25-1.42) 
Cardiovascular death     
  <120/<70 100  114,978  87  0.91 (0.74-1.12) 
  120–129/70–79 580  380,897  152  0.94 (0.85-1.05) 
  130–139/80–89 978  470,149  208  1.00 (reference) 
  140–149/90–99 628  212,990  295  1.15 (1.04-1.27) 
  ≥150/≥100 485  89,386  543  1.58 (1.41-1.76) 
MI     
  <120/<70 107  116,521  92  0.93 (0.76-1.15) 
  120–129/70–79 488  387,247  126  0.96 (0.86-1.08) 
  130–139/80–89 715  480,447  149  1.00 (reference) 
  140–149/90–99 435  219,869  198  1.20 (1.07-1.36) 
  ≥150/≥100 228  94,765  241  1.29 (1.11-1.50) 
Stroke     
  <120/<70 417  114,778  363  0.61 (0.55-0.67) 
  120–129/70–79 2,536  374,842  677  0.85 (0.81-0.89) 
  130–139/80–89 4,155  458,532  906  1.00 (reference) 
  140–149/90–99 2,408  206,666  1,165  1.16 (1.10-1.22) 
  ≥150/≥100 1,320  87,509  1,508  1.29 (1.21-1.37) 
Cardiovascular death or MI or stroke 
  <120/<70 577  113,862  507  0.69 (0.63-0.75) 
  120–129/70–79 3,256  371,071  877  0.87 (0.83-0.91) 
  130–139/80–89 5,259  452,615  1,162  1.00 (reference) 
  140–149/90–99 3,065  203,211  1,508  1.15 (1.10-1.21) 
  ≥150/≥100 1,750  85,106  2,056  1.33 (1.26-1.41) 
HR was adjusted for age, sex, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
and medication (aspirin or statin), and antihypertensive medication. CI, confidence interval; HR, hazard ratio; and MI, myocardial infarction. 
 
Table S12. Incidences of Major Cardiovascular Events According to Blood Pressure Level in Patients without Diabetes.  
Blood pressure (mmHg) Events (n) Person-years Incidence  
(events/100,000 person-years) 
Adjusted HR (95% CI) 
In total population     
All-cause death     
  <120/<70 1,465 179,776 815 1.20 (1.14-1.27) 
  120–129/70–79 8,079 939,591 860 1.01 (0.98-1.04) 
  130–139/80–89 14,731 1,636,421 900 1.00 (reference) 
  140–149/90–99 9,488 833,369 1,139 1.11 (1.08-1.14) 
  ≥150/≥100 6,505 362,596 1,794 1.39 (1.35-1.44) 
Cardiovascular death     
  <120/<70 371 179,776 206 1.25 (1.12-1.39) 
  120–129/70–79 1,992 939,591 212 1.01 (0.96-1.07) 
  130–139/80–89 3,623 1,636,421 221 1.00 (reference) 
  140–149/90–99 2,511 833,369 301 1.18 (1.12-1.24) 
  ≥150/≥100 1,901 362,596 524 1.61 (1.53-1.71) 
MI     
  <120/<70 273 184,722 148 0.95 (0.83-1.07) 
  120–129/70–79 1,720 962,972 179 0.99 (0.94-1.05) 
  130–139/80–89 3,117 1,679,385 186 Ref 
  140–149/90–99 1,762 865,297 204 1.05 (0.99-1.11) 
  ≥150/≥100 950 388,354 245 1.16 (1.08-1.25) 
Stroke     
  <120/<70 883 181,277 487 0.67 (0.62-0.72) 
  120–129/70–79 6,782 932,541 727 0.87 (0.85-0.90) 
  130–139/80–89 13,743 1,613,191 852 1.00 (reference) 
  140–149/90–99 8,548 821,764 1,040 1.13 (1.10-1.16) 
  ≥150/≥100 5,002 362,425 1,380 1.31 (1.27-1.35) 
Cardiovascular death or MI or stroke 
  <120/<70 1,372 178,593 768 0.79 (0.75-0.83) 
  120–129/70–79 9,421 918,616 1,026 0.91 (0.89-0.93) 
  130–139/80–89 18,439 1,588,185 1,161 1.00 (reference) 
  140–149/90–99 11,358 806,779 1,408 1.12 (1.10-1.15) 
  ≥150/≥100 6,784 352,756 1,923 1.33 (1.29-1.37) 
In Men     
All-cause death     
  <120/<70 740 44,178 1,675 1.25 (1.16-1.35) 
  120–129/70–79 4,298 359,441 1,196 1.04 (1.00-1.08) 
  130–139/80–89 8,313 762,451 1,090 1.00 (reference) 
  140–149/90–99 5,353 400,574 1,336 1.11 (1.07-1.15) 
  ≥150/≥100 3,593 171,372 2,097 1.42 (1.37-1.48) 
Cardiovascular death     
  <120/<70 177 44,178 401 1.33 (1.14-1.56) 
  120–129/70–79 943 359,441 262 1.02 (0.95-1.11) 
  130–139/80–89 1,843 762,451 242 1.00 (reference) 
  140–149/90–99 1,261 400,574 315 1.18 (1.10-1.27) 
  ≥150/≥100 934 171,372 545 1.66 (1.53-1.80) 
MI     
  <120/<70 140 46,868 299 1.14 (0.96-1.35) 
  120–129/70–79 966 371,973 260 1.06 (0.98-1.15) 
  130–139/80–89 1,860 787,021 236 1.00 (reference) 
  140–149/90–99 1,007 419,583 240 1.00 (0.93-1.08) 
  ≥150/≥100 507 186,707 272 1.08 (0.98-1.19) 
Stroke     
  <120/<70 315 45,782 688 0.71 (0.63-0.79) 
  120–129/70–79 2,856 360,560 792 0.91 (0.87-0.95) 
  130–139/80–89 6,319 758,470 833 1.00 (reference) 
  140–149/90–99 4,008 399,651 1,003 1.14 (1.09-1.18) 
  ≥150/≥100 2,405 174,514 1,378 1.37 (1.30-1.43) 
Cardiovascular death or MI or stroke 
  <120/<70 557 44,444 1,253 0.88 (0.81-0.96) 
  120–129/70–79 4,289 352,524 1,217 0.96 (0.92-0.99) 
  130–139/80–89 9,035 743,375 1,215 1.00 (reference) 
  140–149/90–99 5,551 391,129 1,419 1.11 (1.07-1.15) 
  ≥150/≥100 3,334 169,331 1,969 1.36 (1.30-1.41) 
In Women     
All-cause death     
  <120/<70 725 135,597 535 1.29 (1.20-1.40) 
  120–129/70–79 3,781 580,150 652 1.03 (0.99-1.08) 
  130–139/80–89 6,418 873,969 734 1.00 (reference) 
  140–149/90–99 4,135 432,795 955 1.09 (1.05-1.14) 
  ≥150/≥100 2,912 191,224 1,523 1.33 (1.28-1.39) 
Cardiovascular death     
  <120/<70 194 135,597 143 1.28 (1.11-1.49) 
  120–129/70–79 1,049 580,150 181 1.04 (0.97-1.13) 
  130–139/80–89 1,780 873,969 204 1.00 (reference) 
  140–149/90–99 1,250 432,795 289 1.18 (1.10-1.27) 
  ≥150/≥100 967 191,224 506 1.55 (1.43-1.68) 
MI     
  <120/<70 133 137,854 96 0.96 (0.80-1.15) 
  120–129/70–79 754 590,998 128 0.99 (0.90-1.08) 
  130–139/80–89 1,257 892,363 141 1.00 (reference) 
  140–149/90–99 755 445,713 169 1.09 (1.00-1.20) 
  ≥150/≥100 443 201,647 220 1.24 (1.11-1.38) 
Stroke     
  <120/<70 568 135,495 419 0.66 (0.61-0.72) 
  120–129/70–79 3,926 571,981 686 0.86 (0.82-0.89) 
  130–139/80–89 7,424 854,720 869 1.00 (reference) 
  140–149/90–99 4,540 422,112 1,076 1.13 (1.09-1.17) 
  ≥150/≥100 2,597 187,911 1,382 1.25 (1.20-1.31) 
Cardiovascular death or MI or stroke 
  <120/<70 815 134,148 608 0.78 (0.73-0.84) 
  120–129/70–79 5,132 566,091 907 0.89 (0.86-0.92) 
  130–139/80–89 9,404 844,810 1,113 1.00 (reference) 
  140–149/90–99 5,807 415,649 1,397 1.13 (1.10-1.17) 
  ≥150/≥100 3,450 183,425 1,881 1.29 (1.24-1.35) 
 
HR was adjusted for age, sex, household income, smoking, physical activity, alcohol consumption, body mass index, glucose, total cholesterol, 
and medication (aspirin or statin), and antihypertensive medication. CI, confidence interval; HR, hazard ratio; and MI, myocardial infarction. 
 
 
Figure S1. Categorized study population according to systolic and/or diastolic blood 
pressure. 
 
Uncontrolled BP was defined as SBP ≥150and/orDBP ≥100 mmHg. Lenient BP reduction 
group was defined as SBP ≥140and/orDBP ≥90 mmHg after excluding the uncontrolled BP 
group. In the same way, standard BP reduction was defined as 130–139and/or80–89 mmHg, 
intensive BP reduction as 120–129and/or70–79 mmHg, and extremely intensive BP reduction 
as <120/and70 mmHg, respectively. BP, blood pressure; SBP, systolic blood pressure; DBP, 
diastolic blood pressure. 
 
